fluoranthene - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	fluoranthene	go back to main search page
Accession:	CHEBI:33083	browse the term
Definition:	An ortho- and peri-fused polycyclic arene consisting of a naphthalene and benzene unit connected by a five-membered ring.
Synonyms:	related_synonym:	Formula=C16H10; InChI=1S/C16H10/c1-2-8-13-12(7-1)14-9-3-5-11-6-4-10-15(13)16(11)14/h1-10H; InChIKey=GVEPBJHOBDJJJI-UHFFFAOYSA-N; SMILES=c1ccc-2c(c1)-c1cccc3cccc-2c13; benzo[jk]fluorene
	xref:	Beilstein:1907918; CAS:206-44-0; Gmelin:262216; KEGG:C19425
	xref_mesh:	MESH:C007738
	xref:	MetaCyc:CPD-15564; PMID:15278918; PMID:17258277; PMID:23943046; PMID:24151025; Reaxys:1907918; Wikipedia:Fluoranthene

show annotations for term's descendants Sort by:
Rat (757) Mouse (785) Human (765) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (0) Green Monkey (0) Naked Mole-rat (0) All
Genes (757)

fluoranthene

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alpha-2-macroglobulin

multiple interactions

[Benzo(a)pyrene co-treated with fluoranthene] affects the expression of A2M mRNA

NCBI chr 4:154,897,770...154,947,787
Ensembl chr 4:154,897,877...154,947,786

G

acetoacetyl-CoA synthetase

decreases expression

fluoranthene results in decreased expression of AACS mRNA

NCBI chr12:31,113,098...31,156,411
Ensembl chr12:31,113,098...31,160,954

G

ATP binding cassette subfamily D member 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of ABCD1 mRNA

NCBI chr X:151,428,334...151,450,115
Ensembl chr X:151,428,578...151,450,115

G

ATP binding cassette subfamily D member 3

multiple interactions

[1,2,5,6-dibenzanthracene co-treated with fluoranthene] affects the expression of ABCD3 mRNA

NCBI chr 2:209,852,087...209,905,763
Ensembl chr 2:209,852,087...209,906,020

G

ABL proto-oncogene 2, non-receptor tyrosine kinase

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ABL2 mRNA

NCBI chr13:68,673,702...68,770,846
Ensembl chr13:68,673,722...68,839,742

G

ankyrin repeat and BTB domain containing 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ABTB2 mRNA

NCBI chr 3:89,954,726...90,108,549
Ensembl chr 3:89,954,713...90,108,548

G

acyl-CoA dehydrogenase family, member 10

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of ACAD10 mRNA

NCBI chr12:34,901,211...34,943,973
Ensembl chr12:34,901,219...34,982,521

G

acyl-CoA binding domain containing 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ACBD3 mRNA

NCBI chr13:92,455,813...92,484,556
Ensembl chr13:92,455,655...92,483,380

G

acyl-CoA thioesterase 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ACOT2 mRNA

NCBI chr 6:103,611,738...103,619,404
Ensembl chr 6:103,611,544...103,619,245

G

acyl-CoA oxidase 2

multiple interactions

[1,2,5,6-dibenzanthracene co-treated with fluoranthene] affects the expression of ACOX2 mRNA

NCBI chr15:16,660,584...16,692,160
Ensembl chr15:16,660,272...16,692,160

G

acyl-CoA synthetase long-chain family member 3

decreases expression

fluoranthene results in decreased expression of ACSL3 mRNA

NCBI chr 9:80,115,164...80,164,636
Ensembl chr 9:80,115,112...80,164,627

G

acyl-CoA synthetase long-chain family member 4

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ACSL4 mRNA

NCBI chr X:105,942,794...106,006,573
Ensembl chr X:105,942,799...106,006,427

G

aminoacylase 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of ACY3 mRNA

NCBI chr 1:201,279,751...201,285,803
Ensembl chr 1:201,279,851...201,283,175

G

ADAM metallopeptidase with thrombospondin type 1 motif, 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ADAMTS1 mRNA

NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103

G

ADAM metallopeptidase with thrombospondin type 1 motif, 4

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ADAMTS4 mRNA

NCBI chr13:83,670,556...83,680,045
Ensembl chr13:83,670,183...83,680,065

G

ADAM metallopeptidase with thrombospondin type 1 motif, 5

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of ADAMTS5 mRNA

NCBI chr11:25,000,627...25,047,205
Ensembl chr11:25,000,637...25,047,205

G

adhesion G protein-coupled receptor D1

multiple interactions
decreases expression

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of ADGRD1 mRNA
fluoranthene results in decreased expression of ADGRD1 mRNA

NCBI chr12:27,488,908...27,603,714
Ensembl chr12:27,488,908...27,603,696

G

alcohol dehydrogenase 1C (class I), gamma polypeptide

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ADH1 mRNA

NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892

G

alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide

increases expression
multiple interactions

fluoranthene results in increased expression of ADH7 mRNA
[1-methylanthracene co-treated with fluoranthene] results in increased expression of ADH7 mRNA

NCBI chr 2:226,748,724...226,763,183
Ensembl chr 2:226,741,788...226,763,182

G

acireductone dioxygenase 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of ADI1 mRNA

NCBI chr 6:45,306,885...45,313,847
Ensembl chr 6:45,306,841...45,313,842

G

ALF transcription elongation factor 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of AFF1 mRNA

NCBI chr14:5,861,188...6,024,196
Ensembl chr14:5,863,961...6,024,729

G

AFG2 AAA ATPase homolog A

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of AFG2A mRNA

NCBI chr 2:120,306,417...120,497,707
Ensembl chr 2:120,306,412...120,497,705

G

aftiphilin

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of AFTPH mRNA

NCBI chr14:94,871,429...94,925,625
Ensembl chr14:94,871,429...94,925,376

G

aryl hydrocarbon receptor

multiple interactions
increases activity

[benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [indeno(1,2,3-cd)pyrene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene] promotes the reaction [pyrene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with pyrene] promotes the reaction [fluoranthene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [chrysene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [benzo(k)fluoranthene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [benzo(j)fluoranthene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [Benzo(a)pyrene results in increased activity of AHR protein]; [Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [benz(a)anthracene results in increased activity of AHR protein]; [fluoranthene co-treated with Benzo(a)pyrene] results in increased activity of AHR protein; [naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] results in decreased expression of AHR protein; AHR protein affects the reaction [[naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] results in decreased expression of AR protein]; AHR protein affects the reaction [[naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] results in increased expression of ESR1 protein]; AHRR protein affects the reaction [[naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] results in decreased expression of AHR protein]; fluoranthene promotes the reaction [pyrene results in increased activity of AHR protein]; pyrene promotes the reaction [fluoranthene results in increased activity of AHR protein]
fluoranthene analog results in increased activity of AHR protein

PMID:17665671 PMID:25500124 PMID:28710019 PMID:30980910

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

aryl-hydrocarbon receptor repressor

increases expression
multiple interactions

fluoranthene results in increased expression of AHRR mRNA
[naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] results in decreased expression of AHRR protein; AHRR protein affects the reaction [[naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] results in decreased expression of AHR protein]; AHRR protein affects the reaction [[naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] results in decreased expression of CYP1A1 protein]
TNF protein inhibits the reaction [fluoranthene results in increased expression of AHRR mRNA]

PMID:25268939 PMID:28710019 PMID:30980910

NCBI chr 1:28,993,634...29,088,673
Ensembl chr 1:28,993,634...29,088,673

G

adenylate kinase 4

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of AK4 mRNA

NCBI chr 5:116,039,222...116,099,064
Ensembl chr 5:116,039,616...116,098,618

G

aldo-keto reductase family 1 member B1

multiple interactions

[Benzo(a)pyrene co-treated with fluoranthene] affects the expression of AKR1B1 mRNA
[1,2,5,6-dibenzanthracene co-treated with fluoranthene] affects the expression of AKR1B1 mRNA

PMID:17690111 PMID:18711122

NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157

G

aldehyde dehydrogenase 3 family, member A1

increases expression
multiple interactions

fluoranthene results in increased expression of ALDH3A1 mRNA
[1-methylanthracene co-treated with fluoranthene] results in increased expression of ALDH3A1 mRNA

NCBI chr10:45,892,993...45,902,680
Ensembl chr10:45,892,924...45,902,681

G

aldolase, fructose-bisphosphate B

multiple interactions

[Benzo(a)pyrene co-treated with fluoranthene] affects the expression of ALDOB mRNA

NCBI chr 5:63,889,045...63,902,086
Ensembl chr 5:63,889,046...63,902,116

G

alkB homolog 7

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of ALKBH7 mRNA

NCBI chr 9:1,838,886...1,841,044
Ensembl chr 9:1,838,811...1,841,044

G

adenosine monophosphate deaminase 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of AMPD3 mRNA

NCBI chr 1:164,884,823...164,929,899
Ensembl chr 1:164,885,320...164,929,887

G

angiopoietin-like 4

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ANGPTL4 mRNA

NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519

G

ankyrin repeat domain containing 11

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ANKRD11 mRNA

NCBI chr19:50,940,284...51,098,962
Ensembl chr19:50,940,299...51,098,962

G

ankyrin repeat domain 37

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of ANKRD37 mRNA

NCBI chr16:46,268,933...46,271,971
Ensembl chr16:46,268,443...46,271,963

G

ANTXR cell adhesion molecule 2

increases expression
multiple interactions

fluoranthene results in increased expression of ANTXR2 mRNA
[1-methylanthracene co-treated with fluoranthene] results in increased expression of ANTXR2 mRNA

NCBI chr14:11,541,718...11,682,110
Ensembl chr14:11,541,772...11,682,094

G

adaptor related protein complex 1 subunit sigma 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of AP1S1 mRNA

NCBI chr12:19,625,267...19,635,792
Ensembl chr12:19,625,332...19,756,713

G

apelin

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of APLN mRNA

NCBI chr X:127,180,801...127,213,567
Ensembl chr X:127,203,823...127,213,391

G

apolipoprotein B receptor

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of APOBR mRNA

NCBI chr 1:181,169,019...181,173,206
Ensembl chr 1:181,168,916...181,173,528

G

apolipoprotein C3

multiple interactions

[Benzo(a)pyrene co-treated with fluoranthene] affects the expression of APOC3 mRNA

NCBI chr 8:46,531,478...46,533,658
Ensembl chr 8:46,531,478...46,533,583

G

androgen receptor

multiple interactions

[naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] results in decreased expression of AR protein; AHR protein affects the reaction [[naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] results in decreased expression of AR protein]; fluoranthene binds to and results in decreased activity of AR protein; fluoranthene inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]; fluoranthene inhibits the reaction [Metribolone results in increased activity of AR protein]

PMID:10771140 PMID:18324785 PMID:30980910 PMID:33049310

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ARAP2 mRNA

NCBI chr14:46,717,657...46,917,326
Ensembl chr14:46,718,760...46,917,154

G

ADP-ribosylation factor GTPase activating protein 1

multiple interactions

[Benzo(a)pyrene co-treated with fluoranthene] affects the expression of ARFGAP1 mRNA

NCBI chr 3:168,084,560...168,099,948
Ensembl chr 3:168,084,614...168,099,933

G

Rho/Rac guanine nucleotide exchange factor 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ARHGEF2 mRNA

NCBI chr 2:174,061,126...174,118,355
Ensembl chr 2:174,062,976...174,118,355

G

Rho guanine nucleotide exchange factor 28

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ARHGEF28 mRNA

NCBI chr 2:29,263,888...29,560,595
Ensembl chr 2:29,263,886...29,560,672

G

AT-rich interaction domain 5A

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ARID5A mRNA

NCBI chr 9:38,534,612...38,549,467
Ensembl chr 9:38,534,590...38,547,597

G

ADP-ribosylation factor like GTPase 2 binding protein

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of ARL2BP mRNA

NCBI chr19:10,336,921...10,346,555
Ensembl chr19:10,336,921...10,346,564

G

ADP-ribosylation factor like GTPase 5B

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ARL5B mRNA

NCBI chr17:77,955,864...77,979,895
Ensembl chr17:77,955,818...77,979,854

G

aryl hydrocarbon receptor nuclear translocator

multiple interactions

[naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] affects the expression of ARNT protein; [naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] results in decreased expression of ARNT mRNA; [naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] results in increased expression of ARNT mRNA

NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580

G

arrestin domain containing 4

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of ARRDC4 mRNA

NCBI chr 1:122,369,355...122,383,351
Ensembl chr 1:122,369,360...122,383,290

G

arylsulfatase family, member J

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of ARSJ mRNA

NCBI chr 2:214,774,631...214,854,614
Ensembl chr 2:214,774,654...214,854,612

G

ArfGAP with SH3 domain, ankyrin repeat and PH domain 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ASAP2 mRNA

NCBI chr 6:40,658,201...40,821,017
Ensembl chr 6:40,657,880...40,820,975

G

activating signal cointegrator 1 complex subunit 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ASCC3 mRNA

NCBI chr20:53,510,137...53,795,446
Ensembl chr20:53,510,184...53,790,165

G

activating transcription factor 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ATF3 mRNA

NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631

G

activating transcription factor 4

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ATF4 mRNA

NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446

G

atonal bHLH transcription factor 8

increases expression

fluoranthene results in increased expression of ATOH8 mRNA

NCBI chr 4:104,259,992...104,292,168
Ensembl chr 4:104,259,992...104,292,168

G

antioxidant 1 copper chaperone

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of ATOX1 mRNA

NCBI chr10:39,564,855...39,579,892
Ensembl chr10:39,564,857...39,579,950

G

ATP23 metallopeptidase and ATP synthase assembly factor homolog

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of ATP23 mRNA

NCBI chr 7:62,714,752...62,729,893
Ensembl chr 7:62,714,785...62,729,862

G

AVL9 cell migration associated

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of AVL9 mRNA

NCBI chr 4:85,961,493...86,008,347
Ensembl chr 4:85,961,635...86,008,791

G

axin 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of AXIN2 mRNA

NCBI chr10:93,893,830...93,927,042
Ensembl chr10:93,899,245...93,926,231

G

BCL2 associated X, apoptosis regulator

multiple interactions

[Benzo(a)pyrene co-treated with fluoranthene] affects the expression of BAX mRNA

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

Bardet-Biedl syndrome 7

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of BBS7 mRNA

NCBI chr 2:119,434,760...119,474,665
Ensembl chr 2:119,434,760...119,474,396

G

BCAR3 adaptor protein, NSP family member

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of BCAR3 mRNA

NCBI chr 2:210,525,260...210,638,674
Ensembl chr 2:210,525,260...210,638,798

G

BCL10, immune signaling adaptor

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of BCL10 mRNA

NCBI chr 2:234,840,880...234,850,520
Ensembl chr 2:234,840,858...234,850,523

G

BCL3, transcription coactivator

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of BCL3 mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of BCL3 mRNA]

NCBI chr 1:79,471,368...79,485,908
Ensembl chr 1:79,471,369...79,485,607

G

BCL6, transcription repressor

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of BCL6 mRNA

NCBI chr11:76,854,090...76,877,389
Ensembl chr11:76,854,090...76,877,389

G

BCL9, transcription coactivator

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of BCL9 mRNA

NCBI chr 2:184,760,616...184,846,261
Ensembl chr 2:184,760,618...184,786,435

G

brain-derived neurotrophic factor

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of BDNF mRNA

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

baculoviral IAP repeat-containing 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of BIRC3 mRNA

NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802

G

basic leucine zipper nuclear factor 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of BLZF1 mRNA

NCBI chr13:76,641,757...76,656,977
Ensembl chr13:76,641,515...76,656,999

G

BMP-2 inducible kinase

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of BMP2K mRNA

NCBI chr14:12,481,194...12,579,411
Ensembl chr14:12,484,729...12,579,134

G

BCL2 interacting protein 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of BNIP3 mRNA

NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359

G

bromodomain containing 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of BRD1 mRNA

NCBI chr 7:119,774,187...119,822,032
Ensembl chr 7:119,774,188...119,822,031

G

B-TFIID TATA-box binding protein associated factor 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of BTAF1 mRNA

NCBI chr 1:234,653,219...234,743,903
Ensembl chr 1:234,653,156...234,743,903

G

BTG anti-proliferation factor 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of BTG1 mRNA

NCBI chr 7:31,341,391...31,343,649
Ensembl chr 7:31,341,027...31,343,649

G

BTG anti-proliferation factor 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of BTG2 mRNA

NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628

G

similar to human chromosome 21 open reading frame 91

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of D16ERTD472E mRNA

NCBI chr11:17,229,129...17,262,307
Ensembl chr11:17,229,138...17,262,483

G

complement C1r subcomponent like

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of C1RL mRNA

NCBI chr 4:157,394,183...157,410,771
Ensembl chr 4:157,394,200...157,410,134

G

calmodulin 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of CALM3 mRNA

NCBI chr 1:77,590,668...77,597,776
Ensembl chr 1:77,589,230...77,592,207

G

calcyphosine

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of TNFRSF23 mRNA

NCBI chr 9:1,544,597...1,545,631
Ensembl chr 9:1,544,719...1,545,647

G

cysteinyl-tRNA synthetase 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of CARS1 mRNA

NCBI chr 1:198,753,689...198,796,016
Ensembl chr 1:198,753,691...198,795,941

G

caspase 4

multiple interactions
increases expression

[1-methylanthracene co-treated with fluoranthene] results in increased expression of CASP4 mRNA
fluoranthene results in increased expression of CASP4 mRNA

NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092

G

caspase 6

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of CASP6 mRNA

NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502

G

caveolae associated protein 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of CAVIN1 mRNA

NCBI chr10:85,884,100...85,896,136
Ensembl chr10:85,889,036...85,896,120

G

caveolae associated protein 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of CAVIN3 mRNA

NCBI chr 1:159,826,549...159,828,138
Ensembl chr 1:159,826,549...159,828,161

G

chibby 1, beta catenin antagonist

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of CBY1 mRNA

NCBI chr 7:111,216,835...111,223,305

G

coiled-coil domain containing 186

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of CCDC186 mRNA

NCBI chr 1:255,831,663...255,871,954
Ensembl chr 1:255,839,595...255,871,935

G

C-C motif chemokine ligand 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of CCL2 mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of CCL2 mRNA]

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 7

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of CCL7 mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of CCL7 mRNA]

NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303

G

cellular communication network factor 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of CCN1 mRNA

NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484

G

cyclin A2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of CCNA2 mRNA

NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577

G

cyclin D1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of CCND1 mRNA

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin E2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of CCNE2 mRNA

NCBI chr 5:24,285,078...24,298,258
Ensembl chr 5:24,284,922...24,297,632

G

cyclin L1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of CCNL1 mRNA

NCBI chr 2:150,184,865...150,199,524
Ensembl chr 2:150,184,798...150,197,368

G

C-C motif chemokine receptor 7

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of CCR7 mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of CCR7 mRNA]

NCBI chr10:84,098,193...84,108,309
Ensembl chr10:84,097,381...84,108,309

G

coiled-coil serine-rich protein 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of CCSER1 mRNA

NCBI chr 4:90,153,873...91,391,441
Ensembl chr 4:90,292,780...91,388,786

G

CDC42 effector protein 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of CDC42EP3 mRNA

NCBI chr 6:15,710,894...15,731,366
Ensembl chr 6:15,708,730...15,732,721

G

cell division cycle 6

multiple interactions
decreases expression

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of CDC6 mRNA
fluoranthene results in decreased expression of CDC6 mRNA

NCBI chr10:83,864,189...83,878,011
Ensembl chr10:83,864,638...83,878,011

G

cadherin 1

multiple interactions

[Benzo(a)pyrene co-treated with fluoranthene] affects the expression of CDH1 mRNA

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

cadherin 17

multiple interactions

[1,2,5,6-dibenzanthracene co-treated with fluoranthene] affects the expression of CDH17 mRNA

NCBI chr 5:25,262,820...25,314,884
Ensembl chr 5:25,262,758...25,314,884

G

CDP-diacylglycerol--inositol 3-phosphatidyltransferase

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of CDIPT mRNA

NCBI chr 1:181,583,098...181,587,409
Ensembl chr 1:181,583,141...181,587,408

G

cyclin-dependent kinase 18

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of CDK18 mRNA

NCBI chr13:43,555,597...43,582,210
Ensembl chr13:43,556,748...43,588,525

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

[Benzo(a)pyrene co-treated with fluoranthene] affects the expression of CDKN1A mRNA
[1-methylanthracene co-treated with fluoranthene] results in increased expression of CDKN1A mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of CDKN1A mRNA]

PMID:17690111 PMID:28329830

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 2C

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of CDKN2C mRNA

NCBI chr 5:124,411,123...124,416,278
Ensembl chr 5:124,411,124...124,416,278

G

cell adhesion associated, oncogene regulated

multiple interactions
decreases expression

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of CDON mRNA
fluoranthene results in decreased expression of CDON mRNA

NCBI chr 8:33,775,123...33,861,635
Ensembl chr 8:33,806,183...33,859,033

G

cerebellar degeneration-related protein 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of CDR2 mRNA

NCBI chr 1:175,502,837...175,527,746
Ensembl chr 1:175,502,838...175,537,472

G

CCAAT/enhancer binding protein beta

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of CEBPB mRNA

NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473

G

CCAAT/enhancer binding protein delta

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of CEBPD mRNA

NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829

G

CCAAT/enhancer binding protein gamma

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of CEBPG mRNA

NCBI chr 1:87,683,060...87,692,772
Ensembl chr 1:87,684,019...87,694,569

G

CCAAT/enhancer binding protein zeta

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of CEBPZ mRNA

NCBI chr 6:16,119,871...16,137,600
Ensembl chr 6:16,119,872...16,137,600

G

CEBPZ opposite strand

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of CEBPZOS mRNA

NCBI chr 6:16,135,546...16,140,143
Ensembl chr 6:16,133,410...16,140,151

G

cell migration inducing hyaluronidase 1

decreases expression

fluoranthene results in decreased expression of CEMIP mRNA

NCBI chr 1:137,906,921...138,062,430
Ensembl chr 1:137,908,920...138,062,415

G

centromere protein X

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of CENPX mRNA

NCBI chr10:105,991,469...105,994,310

G

centrosomal protein 85-like

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of CEP85L mRNA

NCBI chr20:32,568,417...32,739,449
Ensembl chr20:32,572,741...32,739,516

G

ChaC glutathione-specific gamma-glutamylcyclotransferase 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of CHAC1 mRNA

NCBI chr 3:106,342,302...106,345,526
Ensembl chr 3:106,342,302...106,345,526

G

chromodomain helicase DNA binding protein 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of CHD2 mRNA

NCBI chr 1:127,188,146...127,317,041
Ensembl chr 1:127,190,059...127,300,502

G

checkpoint kinase 2

increases expression
multiple interactions

fluoranthene results in increased expression of CHEK2 mRNA
[1-methylanthracene co-treated with fluoranthene] results in increased expression of CHEK2 mRNA

NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286

G

cysteine-rich hydrophobic domain 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of CHIC2 mRNA

NCBI chr14:33,157,669...33,192,015
Ensembl chr14:33,157,537...33,191,895

G

choline kinase alpha

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of CHKA mRNA

NCBI chr 1:201,076,804...201,125,517
Ensembl chr 1:201,076,860...201,125,516

G

carbohydrate sulfotransferase 12

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of CHST12 mRNA

NCBI chr12:14,110,631...14,129,099
Ensembl chr12:14,110,393...14,129,057

G

claudin 25

multiple interactions
increases expression

[1-methylanthracene co-treated with fluoranthene] results in increased expression of CLDN25 mRNA
fluoranthene results in increased expression of CLDN25 mRNA

NCBI chr 8:49,391,930...49,392,664
Ensembl chr 8:49,391,975...49,392,664

G

claudin 7

multiple interactions

[1,2,5,6-dibenzanthracene co-treated with fluoranthene] affects the expression of CLDN7 mRNA; [Benzo(a)pyrene co-treated with fluoranthene] affects the expression of CLDN7 mRNA

NCBI chr10:54,689,684...54,692,177
Ensembl chr10:54,689,987...54,692,171

G

CDC-like kinase 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of CLK1 mRNA

NCBI chr 9:59,947,774...59,959,002
Ensembl chr 9:59,947,764...59,957,000

G

CDC-like kinase 4

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of CLK4 mRNA

NCBI chr10:35,523,382...35,541,387
Ensembl chr10:35,524,755...35,541,352

G

cap methyltransferase 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of CMTR2 mRNA

NCBI chr19:38,190,718...38,197,549
Ensembl chr19:38,190,642...38,197,804

G

cyclin and CBS domain divalent metal cation transport mediator 4

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of CNNM4 mRNA

NCBI chr 9:38,711,726...38,750,942
Ensembl chr 9:38,711,710...38,750,942

G

catechol-O-methyltransferase

multiple interactions

[naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] affects the expression of COMT mRNA; [naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] results in increased expression of and affects the activity of COMT protein

NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642

G

coordinator of PRMT5 and differentiation stimulator

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of COPRS mRNA

NCBI chr16:75,721,264...75,726,375
Ensembl chr16:75,720,061...75,726,375

G

coenzyme Q10B

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of COQ10B mRNA

NCBI chr 9:56,553,751...56,573,671
Ensembl chr 9:56,553,758...56,573,663

G

cytochrome c oxidase assembly factor COX20

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of COX20 mRNA

NCBI chr13:90,065,900...90,075,386

G

ceruloplasmin

multiple interactions

[Benzo(a)pyrene co-treated with fluoranthene] affects the expression of CP mRNA

NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075

G

cytoplasmic polyadenylation element binding protein 4

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of CPEB4 mRNA

NCBI chr10:15,717,794...15,780,482
Ensembl chr10:15,717,794...15,780,603

G

coproporphyrinogen oxidase

increases expression
multiple interactions

fluoranthene results in increased expression of CPOX mRNA
[1-methylanthracene co-treated with fluoranthene] results in increased expression of CPOX mRNA

NCBI chr11:41,936,585...41,946,568
Ensembl chr11:41,936,591...41,946,746

G

carnitine palmitoyltransferase 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of CPT2 mRNA

NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095

G

cAMP responsive element binding protein 5

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of CREB5 mRNA

NCBI chr 4:82,393,091...82,794,320
Ensembl chr 4:82,393,730...82,790,325

G

CREB3 regulatory factor

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of CREBRF mRNA

NCBI chr10:16,399,170...16,479,650
Ensembl chr10:16,404,596...16,461,999

G

cysteine rich protein 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of CRIP1 mRNA

NCBI chr 6:132,226,746...132,234,620
Ensembl chr 6:132,226,746...132,234,620

G

cold shock domain containing C2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of CSDC2 mRNA

NCBI chr 7:113,451,998...113,466,464
Ensembl chr 7:113,451,998...113,466,463

G

chondroitin sulfate N-acetylgalactosaminyltransferase 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of CSGALNACT2 mRNA

NCBI chr 4:151,271,774...151,308,856
Ensembl chr 4:151,277,645...151,308,839

G

cysteine and serine rich nuclear protein 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of CSRNP1 mRNA

NCBI chr 8:119,704,712...119,717,767
Ensembl chr 8:119,704,713...119,718,183

G

CTTNBP2 N-terminal like

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of CTTNBP2NL mRNA

NCBI chr 2:192,507,963...192,554,548
Ensembl chr 2:192,507,963...192,541,101

G

C-X-C motif chemokine ligand 10

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of CXCL10 mRNA

NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975

G

C-X-C motif chemokine ligand 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of CXCL1 mRNA

NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
increases expression
affects expression
decreases activity

[fluoranthene co-treated with pyrene co-treated with benz(a)anthracene co-treated with chrysene co-treated with benzo(b)fluoranthene co-treated with benzo(k)fluoranthene co-treated with Benzo(a)pyrene] results in increased expression of CYP1A1 mRNA
[fluoranthene co-treated with pyrene] promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]; [naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] affects the expression of CYP1A1 mRNA; [naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] affects the expression of CYP1A1 protein; [naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] results in decreased expression of CYP1A1 protein; AHRR protein affects the reaction [[naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] results in decreased expression of CYP1A1 protein]; fluoranthene promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]
fluoranthene results in increased expression of CYP1A1 mRNA; fluoranthene results in increased expression of CYP1A1 protein
fluoranthene affects the expression of CYP1A1 mRNA
fluoranthene results in decreased activity of CYP1A1 protein
1,2,5,6-dibenzanthracene promotes the reaction [fluoranthene results in increased expression of CYP1A1 mRNA]; Benzo(a)pyrene promotes the reaction [fluoranthene results in increased expression of CYP1A1 mRNA]; fluoranthene affects the reaction [Benzo(a)pyrene affects the expression of CYP1A1 mRNA]; fluoranthene inhibits the reaction [benzo(k)fluoranthene results in increased activity of CYP1A1 protein]; fluoranthene inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; fluoranthene promotes the reaction [1,2,5,6-dibenzanthracene results in increased expression of CYP1A1 mRNA]; fluoranthene promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]; TNF protein inhibits the reaction [fluoranthene results in increased expression of CYP1A1 mRNA]

PMID:7750161 PMID:9586956 PMID:12107646 PMID:16269432 PMID:18711122 More...

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

increases expression
multiple interactions

fluoranthene results in increased expression of CYP1A2 mRNA
[1,2,5,6-dibenzanthracene co-treated with fluoranthene] affects the expression of CYP1A2 mRNA; [Benzo(a)pyrene co-treated with fluoranthene] affects the expression of CYP1A2 mRNA
[fluoranthene co-treated with pyrene co-treated with benz(a)anthracene co-treated with chrysene co-treated with benzo(b)fluoranthene co-treated with benzo(k)fluoranthene co-treated with Benzo(a)pyrene] results in increased expression of CYP1A2 mRNA

PMID:7750161 PMID:12107646 PMID:18711122 PMID:21784029

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 1, subfamily b, polypeptide 1

decreases activity
multiple interactions
increases expression
affects expression

[fluoranthene results in decreased activity of CYP1B1 protein] which results in decreased activity of dibenzo(a,l)pyrene
[1-methylanthracene co-treated with fluoranthene co-treated with Benzo(a)pyrene] results in increased expression of CYP1B1 mRNA; [1-methylanthracene co-treated with fluoranthene] results in increased expression of CYP1B1 mRNA
fluoranthene results in increased expression of CYP1B1 mRNA
fluoranthene affects the expression of CYP1B1 mRNA
[fluoranthene results in decreased activity of CYP1B1 protein] which results in decreased susceptibility to dibenzo(a,l)pyrene; fluoranthene affects the reaction [Benzo(a)pyrene affects the expression of CYP1B1 mRNA]; TNF protein promotes the reaction [fluoranthene results in increased expression of CYP1B1 mRNA]

PMID:17961608 PMID:25268939 PMID:27099206 PMID:27196671 PMID:28329830 More...

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 2, subfamily b, polypeptide 3

multiple interactions
increases expression

[fluoranthene co-treated with Benzo(a)pyrene] inhibits the reaction [pyrene results in increased expression of CYP2B6 mRNA]; [pyrene co-treated with Benzo(a)pyrene] inhibits the reaction [fluoranthene results in increased expression of CYP2B6 mRNA]; [pyrene co-treated with fluoranthene] results in increased expression of CYP2B6 mRNA; Benzo(a)pyrene inhibits the reaction [fluoranthene results in increased expression of CYP2B6 mRNA]

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, family 2, subfamily e, polypeptide 1

increases expression

fluoranthene results in increased expression of CYP2E1 mRNA

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 51

decreases expression

fluoranthene results in decreased expression of CYP51 mRNA

NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410

G

DNA-damage inducible transcript 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of DDIT3 mRNA

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

DNA-damage-inducible transcript 4

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of DDIT4 mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of DDIT4 mRNA]

NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105

G

DEAD-box helicase 5

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of DDX5 mRNA

NCBI chr10:91,723,508...91,732,210
Ensembl chr10:91,723,508...91,732,283

G

defensin beta 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of DEFB1 mRNA

NCBI chr16:70,298,862...70,313,604
Ensembl chr16:70,298,863...70,313,604

G

Dexi homolog

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of DEXI mRNA

NCBI chr10:5,126,021...5,138,746
Ensembl chr10:5,137,288...5,138,738

G

24-dehydrocholesterol reductase

multiple interactions
decreases expression

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of DHCR24 mRNA
fluoranthene results in decreased expression of DHCR24 mRNA

NCBI chr 5:121,344,552...121,371,124
Ensembl chr 5:121,344,575...121,371,137

G

7-dehydrocholesterol reductase

multiple interactions
decreases expression

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of DHCR7 mRNA
fluoranthene results in decreased expression of DHCR7 mRNA

NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055

G

dehydrogenase/reductase 9

increases expression
multiple interactions

fluoranthene results in increased expression of DHRS9 mRNA
[1-methylanthracene co-treated with fluoranthene] results in increased expression of DHRS9 mRNA

NCBI chr 3:54,147,834...54,170,052
Ensembl chr 3:54,147,803...54,220,241

G

DEAH-box helicase 40

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of DHX40 mRNA

NCBI chr10:71,584,546...71,621,479
Ensembl chr10:71,583,716...71,621,445

G

disco-interacting protein 2 homolog C

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of DIP2C mRNA

NCBI chr17:60,647,346...61,032,467
Ensembl chr17:60,649,065...61,032,305

G

divergent protein kinase domain 1A

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of DIPK1A mRNA

NCBI chr14:1,772,412...1,843,508
Ensembl chr14:1,772,422...1,843,743

G

discs large MAGUK scaffold protein 4

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of DLG4 mRNA

NCBI chr10:54,740,700...54,769,097
Ensembl chr10:54,739,470...54,767,153

G

distal-less homeobox 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of DLX2 mRNA

NCBI chr 3:56,370,238...56,373,581
Ensembl chr 3:56,370,483...56,373,597

G

distal membrane arm assembly component 2 like

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of DMAC2L mRNA

NCBI chr 6:88,205,580...88,223,934
Ensembl chr 6:88,205,700...88,223,933

G

DnaJ heat shock protein family (Hsp40) member B9

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of DNAJB9 mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of DNAJB9 mRNA]

NCBI chr 6:61,270,385...61,276,795
Ensembl chr 6:61,269,913...61,275,063

G

deoxynucleotidyltransferase, terminal, interacting protein 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of DNTTIP2 mRNA

NCBI chr 2:210,374,321...210,386,366
Ensembl chr 2:210,374,289...210,385,581

G

DOT1 like histone lysine methyltransferase

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of DOT1L mRNA

NCBI chr 7:8,918,764...8,959,474
Ensembl chr 7:8,917,786...8,956,475

G

death domain containing 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of DTHD1 mRNA

NCBI chr14:46,670,438...46,673,183

G

dual specificity phosphatase 1

multiple interactions

[1,2,5,6-dibenzanthracene co-treated with fluoranthene] affects the expression of DUSP1 mRNA
[1-methylanthracene co-treated with fluoranthene] results in increased expression of DUSP1 mRNA

PMID:18711122 PMID:28329830

NCBI chr10:16,680,478...16,683,275

G

dual specificity phosphatase 16

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of DUSP16 mRNA

NCBI chr 4:167,546,780...167,630,173
Ensembl chr 4:167,548,155...167,629,980

G

dual specificity phosphatase 4

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of DUSP4 mRNA

NCBI chr16:57,376,659...57,398,161
Ensembl chr16:57,377,229...57,398,138

G

dual specificity phosphatase 5

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of DUSP5 mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of DUSP5 mRNA]

NCBI chr 1:252,538,408...252,555,320
Ensembl chr 1:252,538,449...252,551,818

G

dual specificity phosphatase 6

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of DUSP6 mRNA

NCBI chr 7:34,092,848...34,097,186
Ensembl chr 7:34,092,943...34,097,185

G

dual specificity phosphatase 8

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of DUSP8 mRNA

NCBI chr 1:197,167,392...197,184,285
Ensembl chr 1:197,169,422...197,182,921

G

E2F transcription factor 8

decreases expression

fluoranthene results in decreased expression of E2F8 mRNA

NCBI chr 1:98,565,717...98,584,265
Ensembl chr 1:98,565,717...98,584,098

G

endothelin converting enzyme 1

multiple interactions

[Benzo(a)pyrene co-treated with fluoranthene] affects the expression of ECE1 mRNA

NCBI chr 5:150,077,679...150,179,375
Ensembl chr 5:150,077,644...150,179,371

G

endothelin 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of EDN1 mRNA

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

early endosome antigen 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of EEA1 mRNA

NCBI chr 7:30,554,686...30,722,186
Ensembl chr 7:30,554,552...30,718,487

G

estrogen-induced osteoclastogenesis regulator 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of EEIG1 mRNA

NCBI chr 3:15,822,441...15,854,651
Ensembl chr 3:15,823,144...15,854,643

G

ephrin A2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of EFNA2 mRNA

NCBI chr 7:9,515,635...9,528,071
Ensembl chr 7:9,516,429...9,527,061

G

epidermal growth factor receptor

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of EGFR mRNA

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

egl-9 family hypoxia-inducible factor 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of EGLN1 mRNA

NCBI chr19:52,867,900...52,907,308
Ensembl chr19:52,869,486...52,907,777

G

early growth response 1

increases expression
multiple interactions

fluoranthene results in increased expression of EGR1 mRNA; fluoranthene results in increased expression of EGR1 protein
[1-methylanthracene co-treated with fluoranthene] results in increased expression of EGR1 mRNA

PMID:15342960 PMID:28329830 PMID:29787794

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

early growth response 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of EGR2 mRNA

NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562

G

EH-domain containing 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of EHD2 mRNA

NCBI chr 1:76,639,568...76,658,747
Ensembl chr 1:76,637,482...76,658,783

G

EH-domain containing 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of EHD3 mRNA

NCBI chr 6:21,640,861...21,665,601
Ensembl chr 6:21,639,290...21,665,236

G

enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase

multiple interactions

[1,2,5,6-dibenzanthracene co-treated with fluoranthene] affects the expression of EHHADH mRNA

NCBI chr11:79,241,927...79,275,173
Ensembl chr11:79,241,938...79,275,188

G

EI24, autophagy associated transmembrane protein

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of EI24 mRNA

NCBI chr 8:36,494,289...36,510,653
Ensembl chr 8:36,494,289...36,510,571

G

EP300 interacting inhibitor of differentiation 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of EID1 mRNA

NCBI chr 3:112,922,961...112,924,680
Ensembl chr 3:112,922,668...112,924,752

G

EP300 interacting inhibitor of differentiation 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of EID3 mRNA

NCBI chr 7:20,860,073...20,861,395

G

eukaryotic translation initiation factor 1A

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of EIF1A mRNA

NCBI chr18:39,325,695...39,338,043
Ensembl chr18:39,325,202...39,338,696

G

eukaryotic translation initiation factor 1B

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of EIF1B mRNA

NCBI chr 8:120,203,561...120,206,176
Ensembl chr 8:120,203,451...120,206,176

G

eukaryotic translation initiation factor 2 alpha kinase 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of EIF2AK3 mRNA

NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911

G

elongation factor 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of ELOF1 mRNA

NCBI chr 8:20,645,336...20,650,888
Ensembl chr 8:20,645,336...20,650,579

G

ELOVL fatty acid elongase 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of ELOVL1 mRNA

NCBI chr 5:131,961,478...131,965,961
Ensembl chr 5:131,961,322...131,965,958

G

ELOVL fatty acid elongase 6

multiple interactions
decreases expression

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of ELOVL6 mRNA
fluoranthene results in decreased expression of ELOVL6 mRNA

NCBI chr 2:218,063,682...218,174,767
Ensembl chr 2:218,063,804...218,171,186

G

empty spiracles homeobox 2

multiple interactions
decreases expression

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of EMX2 mRNA
fluoranthene results in decreased expression of EMX2 mRNA

NCBI chr 1:258,626,584...258,633,594
Ensembl chr 1:258,626,584...258,633,594

G

ectodermal-neural cortex 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ENC1 mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of ENC1 mRNA]

NCBI chr 2:28,550,670...28,562,591
Ensembl chr 2:28,550,464...28,562,713

G

endosomal transmembrane epsin interactor 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of ENTREP3 mRNA

NCBI chr 2:174,588,984...174,595,281
Ensembl chr 2:174,589,337...174,595,281

G

enhancer of polycomb homolog 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of EPC1 mRNA

NCBI chr17:54,503,358...54,594,444
Ensembl chr17:54,503,358...54,594,425

G

enhancer of polycomb homolog 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of EPC2 mRNA

NCBI chr 3:33,867,219...33,967,908
Ensembl chr 3:33,867,219...33,967,150

G

Eph receptor A2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of EPHA2 mRNA

NCBI chr 5:153,605,644...153,634,115
Ensembl chr 5:153,605,644...153,634,117

G

epiregulin

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of EREG mRNA

NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062

G

endoplasmic reticulum to nucleus signaling 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ERN1 mRNA

NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029

G

ERBB receptor feedback inhibitor 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ERRFI1 mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of ERRFI1 mRNA]

NCBI chr 5:161,323,981...161,337,289
Ensembl chr 5:161,323,998...161,337,282

G

estrogen receptor 1

multiple interactions
decreases expression

[naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] results in increased expression of ESR1 protein; AHR protein affects the reaction [[naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] results in increased expression of ESR1 protein]; fluoranthene binds to and results in increased activity of ESR1 protein; fluoranthene promotes the reaction [Estradiol results in increased activity of ESR1 protein]; Fulvestrant inhibits the reaction [fluoranthene promotes the reaction [Estradiol results in increased activity of ESR1 protein]]
fluoranthene results in decreased expression of ESR1 protein

PMID:12441364 PMID:18634860 PMID:30980910 PMID:33049310

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

estrogen receptor 2

multiple interactions

fluoranthene binds to and results in increased activity of ESR2 protein

NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919

G

ETS proto-oncogene 2, transcription factor

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ETS2 mRNA

NCBI chr11:35,021,536...35,038,322
Ensembl chr11:35,021,596...35,038,319

G

ETS variant transcription factor 5

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ETV5 mRNA

NCBI chr11:78,608,618...78,666,221
Ensembl chr11:78,608,710...78,666,215

G

coagulation factor III, tissue factor

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of F3 mRNA

NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668

G

fatty acid binding protein 1

multiple interactions

[Benzo(a)pyrene co-treated with fluoranthene] affects the expression of FABP1 mRNA

NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788

G

family with sequence similarity 110, member C

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of FAM110C mRNA

NCBI chr 6:47,638,466...47,644,723
Ensembl chr 6:47,638,276...47,644,634

G

family with sequence similarity 118, member A

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of FAM118A mRNA

NCBI chr 7:116,152,448...116,178,976
Ensembl chr 7:116,146,716...116,178,971

G

family with sequence similarity 136, member A

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of FAM136A mRNA

NCBI chr 4:118,805,129...118,811,046
Ensembl chr 4:118,805,127...118,811,047

G

family with sequence similarity 13, member B

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of FAM13B mRNA

NCBI chr18:26,040,285...26,107,112
Ensembl chr18:26,040,285...26,106,587

G

family with sequence similarity 149, member A

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of FAM149A mRNA

NCBI chr16:46,855,377...46,914,553
Ensembl chr16:46,854,635...46,912,066

G

family with sequence similarity 162, member A

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of FAM162A mRNA

NCBI chr11:64,680,978...64,709,865
Ensembl chr11:64,680,323...64,711,239

G

family with sequence similarity 83, member H

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of FAM83H mRNA

NCBI chr 7:107,716,431...107,724,619
Ensembl chr 7:107,716,431...107,728,672

G

F-box protein 32

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of FBXO32 mRNA

NCBI chr 7:89,731,428...89,764,997
Ensembl chr 7:89,730,232...89,765,436

G

F-box protein 33

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of FBXO33 mRNA

NCBI chr 6:76,900,619...76,934,232
Ensembl chr 6:76,900,631...76,932,669

G

farnesyl diphosphate farnesyl transferase 1

decreases expression
multiple interactions

fluoranthene results in decreased expression of FDFT1 mRNA
[1-methylanthracene co-treated with fluoranthene] results in decreased expression of FDFT1 mRNA

NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287

G

farnesyl diphosphate synthase

multiple interactions
decreases expression

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of FDPS mRNA
fluoranthene results in decreased expression of FDPS mRNA

NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776

G

FYVE, RhoGEF and PH domain containing 6

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of FGD6 mRNA

NCBI chr 7:28,597,609...28,712,908
Ensembl chr 7:28,597,609...28,712,456

G

fibroblast growth factor 18

decreases expression
multiple interactions

fluoranthene results in decreased expression of FGF18 mRNA
[1-methylanthracene co-treated with fluoranthene] results in decreased expression of FGF18 mRNA

NCBI chr10:17,706,011...17,737,702
Ensembl chr10:17,706,174...17,736,818

G

fibroblast growth factor 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of FGF2 mRNA

NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221

G

fibroblast growth factor 21

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of FGF21 mRNA

NCBI chr 1:96,083,360...96,084,911
Ensembl chr 1:96,083,441...96,090,454

G

fibroblast growth factor 5

increases expression
multiple interactions

fluoranthene results in increased expression of FGF5 mRNA
[1-methylanthracene co-treated with fluoranthene] results in increased expression of FGF5 mRNA

NCBI chr14:11,323,827...11,346,164
Ensembl chr14:11,325,334...11,345,997

G

fibroblast growth factor 7

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of FGF7 mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of FGF7 mRNA]

NCBI chr 3:113,280,448...113,333,279
Ensembl chr 3:113,281,283...113,332,929

G

fructosamine-3-kinase-related protein

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of FN3KRP mRNA

NCBI chr10:106,688,413...106,697,137
Ensembl chr10:106,688,439...106,697,134

G

folliculin interacting protein 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of FNIP2 mRNA

NCBI chr 2:164,596,557...164,708,147
Ensembl chr 2:164,598,906...164,707,901

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of FOS mRNA

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

FOS like 1, AP-1 transcription factor subunit

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of FOSL1 mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of FOSL1 mRNA]

NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930

G

FOS like 2, AP-1 transcription factor subunit

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of FOSL2 mRNA

NCBI chr 6:24,297,898...24,319,219
Ensembl chr 6:24,300,956...24,320,034

G

forkhead box F2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of FOXF2 mRNA

NCBI chr17:32,835,730...32,842,547
Ensembl chr17:32,836,777...32,842,176

G

forkhead box J3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of FOXJ3 mRNA

NCBI chr 5:133,140,344...133,228,489
Ensembl chr 5:133,140,884...133,228,489

G

forkhead box O6

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of FOXO6 mRNA

NCBI chr 5:133,856,087...133,876,387
Ensembl chr 5:133,856,072...133,876,573

G

follistatin

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of FST mRNA

NCBI chr 2:46,123,260...46,130,584
Ensembl chr 2:46,123,439...46,130,571

G

fucosyltransferase 11

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of FUT11 mRNA

NCBI chr15:3,598,768...3,602,328
Ensembl chr15:3,598,758...3,602,356

G

frizzled class receptor 2

decreases expression
multiple interactions

fluoranthene results in decreased expression of FZD2 mRNA
[1-methylanthracene co-treated with fluoranthene] results in decreased expression of FZD2 mRNA

NCBI chr10:87,561,866...87,563,776
Ensembl chr10:87,561,326...87,565,334

G

glucose-6-phosphate dehydrogenase

multiple interactions

[Benzo(a)pyrene co-treated with fluoranthene] affects the expression of G6PD mRNA

NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801

G

GRB2-associated binding protein 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of GAB2 mRNA

NCBI chr 1:151,429,844...151,625,708
Ensembl chr 1:151,429,695...151,625,031

G

growth arrest and DNA-damage-inducible, alpha

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of GADD45A mRNA

NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115

G

growth arrest and DNA-damage-inducible, beta

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of GADD45B mRNA

NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046

G

growth arrest and DNA-damage-inducible, gamma

decreases expression
multiple interactions

fluoranthene results in decreased expression of GADD45G mRNA
[1-methylanthracene co-treated with fluoranthene] results in decreased expression of GADD45G mRNA; [1-methylanthracene co-treated with fluoranthene] results in increased expression of GADD45G mRNA

NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610

G

polypeptide N-acetylgalactosaminyltransferase 12

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of GALNT12 mRNA

NCBI chr 5:61,384,575...61,413,346
Ensembl chr 5:61,384,571...61,413,354

G

GATA binding protein 2

decreases expression
multiple interactions

fluoranthene results in decreased expression of GATA2 mRNA
[1-methylanthracene co-treated with fluoranthene] results in decreased expression of GATA2 mRNA

NCBI chr 4:120,654,205...120,667,763
Ensembl chr 4:120,658,986...120,667,761

G

GATA binding protein 4

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of GATA4 mRNA

NCBI chr15:37,459,601...37,531,291
Ensembl chr15:37,459,601...37,505,636

G

GTP cyclohydrolase 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of GCH1 mRNA

NCBI chr15:20,404,267...20,437,727
Ensembl chr15:20,402,527...20,437,698

G

glucokinase

multiple interactions

[Benzo(a)pyrene co-treated with fluoranthene] affects the expression of GCK mRNA

NCBI chr14:80,785,060...80,829,842
Ensembl chr14:80,785,060...80,826,995

G

glial cell derived neurotrophic factor

multiple interactions
increases expression

[1-methylanthracene co-treated with fluoranthene] results in increased expression of GDNF mRNA
fluoranthene results in increased expression of GDNF mRNA

NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209

G

GDP-D-glucose phosphorylase 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of GDPGP1 mRNA

NCBI chr 1:134,184,119...134,193,281
Ensembl chr 1:134,183,696...134,219,783

G

Gfo/Idh/MocA-like oxidoreductase domain containing 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of GFOD1 mRNA

NCBI chr17:21,400,142...21,504,972
Ensembl chr17:21,399,479...21,499,938

G

gap junction protein, alpha 1

multiple interactions
decreases expression
decreases localization

[1-methylanthracene co-treated with fluoranthene co-treated with Benzo(a)pyrene] results in decreased expression of GJA1 mRNA; [1-methylanthracene co-treated with fluoranthene co-treated with Benzo(a)pyrene] results in decreased expression of GJA1 protein; [1-methylanthracene co-treated with fluoranthene] results in increased degradation of and results in decreased expression of GJA1 protein; fluoranthene results in increased degradation of and results in decreased expression of GJA1 protein
fluoranthene results in decreased expression of GJA1 protein
fluoranthene results in decreased localization of GJA1 protein

PMID:28329830 PMID:29170806 PMID:30668803

NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582

G

gap junction protein, beta 1

decreases expression
multiple interactions

fluoranthene results in decreased expression of GJB1 protein
[1-methylanthracene co-treated with fluoranthene] affects the expression of and affects the activity of GJB1 protein; fluoranthene affects the expression of and affects the activity of GJB1 protein; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] affects the expression of and affects the activity of GJB1 protein]; SB 203580 inhibits the reaction [fluoranthene affects the expression of and affects the activity of GJB1 protein]

PMID:25268939 PMID:28329830

NCBI chr X:66,501,848...66,509,783
Ensembl chr X:66,501,820...66,509,925

G

GLIS family zinc finger 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of GLIS2 mRNA

NCBI chr10:10,951,157...10,978,524
Ensembl chr10:10,951,371...10,971,578

G

glutaredoxin

decreases expression

fluoranthene results in decreased expression of GLRX mRNA

NCBI chr 2:5,341,873...5,351,686
Ensembl chr 2:5,341,885...5,351,680

G

glutaredoxin 5

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of GLRX5 mRNA

NCBI chr 6:123,988,461...123,998,545
Ensembl chr 6:123,988,134...123,998,545

G

G protein subunit beta 4

multiple interactions
increases expression

[1-methylanthracene co-treated with fluoranthene] results in increased expression of GNB4 mRNA
fluoranthene results in increased expression of GNB4 mRNA

NCBI chr 2:115,360,746...115,400,680
Ensembl chr 2:115,364,918...115,400,579

G

G protein nucleolar 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of GNL3 mRNA

NCBI chr16:6,207,402...6,213,491
Ensembl chr16:6,207,402...6,213,392

G

golgin A5

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of GOLGA5 mRNA

NCBI chr 6:121,612,389...121,640,552
Ensembl chr 6:121,612,529...121,640,413

G

golgin, RAB6-interacting

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of GORAB mRNA

NCBI chr13:75,745,678...75,762,307
Ensembl chr13:75,745,680...75,762,298

G

G patch domain containing 11

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of GPATCH11 mRNA

NCBI chr 6:16,229,933...16,243,305
Ensembl chr 6:16,233,059...16,243,238

G

glycerol-3-phosphate dehydrogenase 1 like

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of GPD1L mRNA

NCBI chr 8:114,591,103...114,620,771
Ensembl chr 8:114,588,487...114,620,723

G

GRAM domain containing 1B

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of GRAMD1B mRNA

NCBI chr 8:40,654,492...40,893,869
Ensembl chr 8:40,659,182...40,893,925

G

GRAM domain containing 4

multiple interactions
increases expression

[1-methylanthracene co-treated with fluoranthene] results in increased expression of GRAMD4 mRNA
fluoranthene results in increased expression of GRAMD4 mRNA

NCBI chr 7:117,150,398...117,224,056
Ensembl chr 7:117,150,374...117,224,053

G

gasdermin E

increases expression

fluoranthene results in increased expression of GSDME mRNA

NCBI chr 4:79,258,799...79,321,129
Ensembl chr 4:79,257,804...79,320,806

G

GTP binding protein 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of GTPBP2 mRNA

NCBI chr 9:14,813,964...14,823,419
Ensembl chr 9:14,813,964...14,823,241

G

GTP binding protein 4

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of GTPBP4 mRNA

NCBI chr17:61,308,033...61,328,184
Ensembl chr17:61,308,014...61,418,009

G

glycogen synthase 1

multiple interactions
decreases expression

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of GYS1 mRNA
fluoranthene results in decreased expression of GYS1 mRNA

NCBI chr 1:95,915,443...95,935,292
Ensembl chr 1:95,915,443...95,935,292

G

H1.2 linker histone, cluster member

decreases expression

fluoranthene results in decreased expression of H1F2 mRNA

NCBI chr17:41,391,106...41,392,597
Ensembl chr17:41,388,477...41,392,635

G

H2A clustered histone 20

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of H2AC20 mRNA

NCBI chr 2:183,779,879...183,780,357

G

H2A.X variant histone

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of H2AX mRNA
[fluoranthene co-treated with Benzo(a)pyrene] results in increased expression of H2AX protein; [pyrene co-treated with fluoranthene co-treated with Benzo(a)pyrene] results in increased expression of H2AX protein

PMID:28329830 PMID:33249052

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239

G

H2B clustered histone 8

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of H2BC8 mRNA

NCBI chr17:42,708,658...42,709,408

G

3-hydroxyacyl-CoA dehydratase 4

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of HACD4 mRNA

NCBI chr 5:102,887,597...102,915,376
Ensembl chr 5:102,887,588...102,915,338

G

hyaluronan synthase 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of HAS2 mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of HAS2 mRNA]

NCBI chr 7:88,113,326...88,139,337
Ensembl chr 7:88,113,326...88,128,933

G

heparin-binding EGF-like growth factor

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of HBEGF mRNA

NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441

G

host cell factor C1 regulator 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of HCFC1R1 mRNA

NCBI chr10:12,705,139...12,706,852
Ensembl chr10:12,705,077...12,706,850

G

hyperpolarization activated cyclic nucleotide gated potassium and sodium channel 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of HCN2 mRNA

NCBI chr 7:9,969,801...9,988,839
Ensembl chr 7:9,970,368...9,988,841

G

histone deacetylase 4

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of HDAC4 mRNA

NCBI chr 9:92,503,467...92,750,164
Ensembl chr 9:92,507,611...92,750,164

G

HD domain containing 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of HDDC2 mRNA

NCBI chr 1:26,294,030...26,313,914
Ensembl chr 1:26,294,030...26,313,935

G

homocysteine inducible ER protein with ubiquitin like domain 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of HERPUD1 mRNA

NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424

G

hes family bHLH transcription factor 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of HES1 mRNA

NCBI chr11:70,705,763...70,708,176
Ensembl chr11:70,705,764...70,708,192

G

heparan-alpha-glucosaminide N-acetyltransferase

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of HGSNAT mRNA

NCBI chr16:66,105,233...66,137,444
Ensembl chr16:66,105,181...66,136,138

G

hypoxia inducible factor 1 subunit alpha

multiple interactions

[Benzo(a)pyrene co-treated with fluoranthene] affects the expression of HIF1A mRNA

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

HIG1 hypoxia inducible domain family, member 1A

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of HIGD1A mRNA

NCBI chr 8:121,514,152...121,523,382
Ensembl chr 8:121,514,156...121,523,443

G

histone H4 transcription factor

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of HINFP mRNA

NCBI chr 8:44,634,333...44,644,288
Ensembl chr 8:44,634,333...44,641,000

G

HIVEP zinc finger 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of HIVEP2 mRNA

NCBI chr 1:8,358,205...8,555,993
Ensembl chr 1:8,359,289...8,555,993

G

high mobility group AT-hook 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of HMGA2 mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of HMGA2 mRNA]

NCBI chr 7:55,877,145...55,998,813
Ensembl chr 7:55,880,112...55,994,784

G

3-hydroxy-3-methylglutaryl-CoA reductase

decreases expression
multiple interactions

fluoranthene results in decreased expression of HMGCR mRNA
[1-methylanthracene co-treated with fluoranthene] results in decreased expression of HMGCR mRNA

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

3-hydroxy-3-methylglutaryl-CoA synthase 1

multiple interactions
decreases expression

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of HMGCS1 mRNA
fluoranthene results in decreased expression of HMGCS1 mRNA

NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100

G

heme oxygenase 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of HMOX1 mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of HMOX1 mRNA]

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heparan sulfate 6-O-sulfotransferase 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of HS6ST1 mRNA

NCBI chr 9:38,283,502...38,322,684
Ensembl chr 9:38,282,395...38,322,683

G

heat shock factor binding protein 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of HSBP1 mRNA

NCBI chr19:47,401,039...47,405,373
Ensembl chr19:47,400,966...47,435,821

G

hydroxysteroid 11-beta dehydrogenase 1

multiple interactions

[1,2,5,6-dibenzanthracene co-treated with fluoranthene] affects the expression of HSD11B1 mRNA

NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687

G

hydroxysteroid (17-beta) dehydrogenase 7

multiple interactions
decreases expression

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of HSD17B7 mRNA
fluoranthene results in decreased expression of HSD17B7 mRNA

NCBI chr13:82,170,079...82,190,018
Ensembl chr13:82,173,179...82,190,017

G

heat shock protein family A (Hsp70) member 1B

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of HSPA1B mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of HSPA1B mRNA]

NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240
Ensembl chr20:3,856,006...3,873,240

G

heat shock protein family A (Hsp70) member 5

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of HSPA5 mRNA

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

intercellular adhesion molecule 1

increases expression

fluoranthene results in increased expression of ICAM1 protein

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

inhibitor of DNA binding 1

multiple interactions
decreases expression

[1,2,5,6-dibenzanthracene co-treated with fluoranthene] affects the expression of ID1 mRNA; [Benzo(a)pyrene co-treated with fluoranthene] affects the expression of ID1 mRNA
fluoranthene results in decreased expression of ID1 mRNA

PMID:18711122 PMID:28329830

NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419

G

isocitrate dehydrogenase (NADP(+)) 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of IDH1 mRNA

NCBI chr 9:66,534,146...66,563,703
Ensembl chr 9:66,534,146...66,563,708

G

isopentenyl-diphosphate delta isomerase 1

decreases expression
multiple interactions

fluoranthene results in decreased expression of IDI1 mRNA
[1-methylanthracene co-treated with fluoranthene] results in decreased expression of IDI1 mRNA

NCBI chr17:61,629,592...61,637,357
Ensembl chr17:61,629,594...61,637,357

G

immediate early response 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of IER2 mRNA

NCBI chr19:23,494,551...23,496,075
Ensembl chr19:23,494,184...23,499,211

G

immediate early response 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of IER3 mRNA

NCBI chr20:2,928,378...2,929,582
Ensembl chr20:2,928,378...2,929,583

G

immediate early response 5

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of IER5 mRNA

NCBI chr13:67,270,134...67,272,226
Ensembl chr13:67,270,135...67,272,227

G

IFI30, lysosomal thiol reductase

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of IFI30 mRNA

NCBI chr16:18,675,590...18,679,655
Ensembl chr16:18,675,613...18,681,175

G

interferon gamma

increases expression

fluoranthene results in increased expression of IFNG mRNA

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interferon-related developmental regulator 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of IFRD1 mRNA

NCBI chr 6:57,269,395...57,317,833
Ensembl chr 6:57,269,384...57,288,990

G

intraflagellar transport 70B

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of IFT70B mRNA

NCBI chr 3:60,855,809...60,858,380
Ensembl chr 3:60,855,575...60,858,389

G

insulin-like growth factor 1

multiple interactions

[Benzo(a)pyrene co-treated with fluoranthene] affects the expression of IGF1 mRNA

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

immunoglobulin superfamily, member 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of IGSF3 mRNA

NCBI chr 2:188,811,394...188,899,645
Ensembl chr 2:188,811,380...188,899,645

G

interleukin 12 receptor subunit beta 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of IL12RB1 mRNA

NCBI chr16:18,620,228...18,633,207
Ensembl chr16:18,620,770...18,632,769

G

interleukin 13 receptor subunit alpha 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of IL13RA1 mRNA

NCBI chr X:115,348,822...115,408,682
Ensembl chr X:115,348,860...115,408,681
Ensembl chr11:115,348,860...115,408,681

G

interleukin 13 receptor subunit alpha 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of IL13RA2 mRNA

NCBI chr X:111,002,590...111,074,053
Ensembl chr X:111,002,592...111,072,381

G

interleukin 17 receptor A

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of IL17RA mRNA

NCBI chr 4:153,667,534...153,690,174
Ensembl chr 4:153,667,534...153,690,174

G

interleukin 22 receptor subunit alpha 1

decreases expression
multiple interactions

fluoranthene results in decreased expression of IL22RA1 mRNA
[1-methylanthracene co-treated with fluoranthene] results in decreased expression of IL22RA1 mRNA

NCBI chr 5:147,961,496...147,986,296
Ensembl chr 5:147,961,349...147,986,296

G

interleukin 4

increases expression
multiple interactions

fluoranthene results in increased expression of IL4 mRNA
TNF protein inhibits the reaction [fluoranthene results in increased expression of IL4 mRNA]

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

interleukin 6

increases expression
increases secretion
multiple interactions

fluoranthene results in increased expression of IL6 mRNA
fluoranthene results in increased secretion of IL6 protein
[1-methylanthracene co-treated with fluoranthene] results in increased expression of IL6 mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of IL6 mRNA]
TNF protein promotes the reaction [fluoranthene results in increased expression of IL6 mRNA]

PMID:18434080 PMID:28329830 PMID:29787794

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

interleukin 6 receptor

multiple interactions
decreases expression

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of IL6RA mRNA
fluoranthene results in decreased expression of IL6RA mRNA

NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536

G

immunoglobulin-like domain containing receptor 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of ILDR2 mRNA

NCBI chr13:78,518,770...78,580,627
Ensembl chr13:78,518,802...78,576,924

G

inka box actin regulator 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of INKA2 mRNA

NCBI chr 2:193,185,275...193,200,643
Ensembl chr 2:193,185,275...193,200,642

G

insulin induced gene 1

decreases expression

fluoranthene results in decreased expression of INSIG1 mRNA

NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952

G

importin 7

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of IPO7 mRNA

NCBI chr 1:164,062,702...164,102,938
Ensembl chr 1:164,062,702...164,102,938

G

IQ motif containing F5

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of IQCF5 mRNA

NCBI chr 8:107,151,477...107,152,862
Ensembl chr 8:107,151,462...107,152,869

G

interleukin-1 receptor-associated kinase 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of IRAK2 mRNA

NCBI chr 4:146,786,004...146,842,615
Ensembl chr 4:146,786,100...146,842,602

G

interferon regulatory factor 1

multiple interactions
increases expression

[1-methylanthracene co-treated with fluoranthene] results in increased expression of IRF1 mRNA
fluoranthene results in increased expression of IRF1 mRNA

NCBI chr10:37,917,155...37,924,166
Ensembl chr10:37,916,670...37,924,166

G

interferon regulatory factor 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of IRF2 mRNA

NCBI chr16:45,439,215...45,550,054
Ensembl chr16:45,439,225...45,550,024

G

interferon regulatory factor 2 binding protein 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of IRF2BP2 mRNA

NCBI chr19:54,559,417...54,565,096
Ensembl chr19:54,560,128...54,566,642

G

interferon regulatory factor 2 binding protein-like

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of IRF2BPL mRNA

NCBI chr 6:106,527,179...106,531,294
Ensembl chr 6:106,528,053...106,530,401

G

immunity-related GTPase M

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of IRGM1 mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of IRGM1 mRNA]

NCBI chr10:33,233,513...33,241,594
Ensembl chr10:33,233,455...33,241,578

G

integrin subunit beta 8

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ITGB8 mRNA

NCBI chr 6:140,125,002...140,208,261
Ensembl chr 6:140,127,203...140,208,476

G

inositol 1,4,5-trisphosphate receptor interacting protein

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ITPRIP mRNA

NCBI chr 1:246,762,804...246,786,379
Ensembl chr 1:246,762,472...246,786,408

G

Jun dimerization protein 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of JDP2 mRNA

NCBI chr 6:105,261,619...105,302,386
Ensembl chr 6:105,261,373...105,301,485

G

jumonji domain containing 1C

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of JMJD1C mRNA

NCBI chr20:21,332,147...21,494,220
Ensembl chr20:21,332,147...21,463,122

G

JRK-like

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of JRKL mRNA

NCBI chr 8:10,224,172...10,227,068
Ensembl chr 8:10,224,172...10,227,068

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of JUN mRNA

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

JunB proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of JUNB mRNA

NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035

G

katanin regulatory subunit B1 like 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of KATNBL1 mRNA

NCBI chr 3:99,183,748...99,225,789
Ensembl chr 3:99,183,716...99,225,786

G

kelch repeat and BTB domain containing 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of KBTBD2 mRNA

NCBI chr 4:86,027,947...86,050,266
Ensembl chr 4:86,027,947...86,050,211

G

potassium channel tetramerization domain containing 21

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of KCTD21 mRNA

NCBI chr 1:151,650,074...151,669,775
Ensembl chr 1:151,650,104...151,667,645

G

lysine demethylase 5A

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of KDM5A mRNA

NCBI chr 4:153,565,909...153,643,912
Ensembl chr 4:153,565,846...153,642,422

G

lysine demethylase 7A

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of KDM7A mRNA

NCBI chr 4:67,899,407...67,974,264
Ensembl chr 4:67,904,307...67,966,998

G

kinesin family member 21B

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of KIF21B mRNA

NCBI chr13:47,576,129...47,626,112
Ensembl chr13:47,576,160...47,626,127

G

KLF transcription factor 10

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of KLF10 mRNA

NCBI chr 7:69,467,658...69,473,726
Ensembl chr 7:69,465,619...69,473,994

G

KLF transcription factor 4

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of KLF4 mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of KLF4 mRNA]

NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602

G

KLF transcription factor 5

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of KLF5 mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of KLF5 mRNA]

NCBI chr15:76,060,320...76,079,445
Ensembl chr15:76,064,258...76,079,445

G

KLF transcription factor 6

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of KLF6 mRNA

NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570

G

KLF transcription factor 9

increases expression
multiple interactions

fluoranthene results in increased expression of KLF9 mRNA
[1-methylanthracene co-treated with fluoranthene] results in increased expression of KLF9 mRNA

NCBI chr 1:220,700,108...220,725,110
Ensembl chr 1:220,700,108...220,725,037

G

kelch-like family member 21

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of KLHL21 mRNA

NCBI chr 5:162,514,888...162,523,545
Ensembl chr 5:162,514,765...162,523,545

G

kelch-like family, member 42

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of KLHL42 mRNA

NCBI chr 4:179,999,655...180,027,283
Ensembl chr 4:180,004,580...180,027,283

G

karyopherin subunit alpha 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of KPNA2 mRNA

NCBI chr10:91,933,951...91,946,115
Ensembl chr10:91,933,951...91,946,150

G

kynurenine aminotransferase 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of KYAT3 mRNA

NCBI chr 2:231,701,881...231,747,462
Ensembl chr 2:231,701,963...231,747,227

G

L-2-hydroxyglutarate dehydrogenase

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of L2HGDH mRNA

NCBI chr 6:88,164,429...88,205,585
Ensembl chr 6:88,164,440...88,205,578

G

lipopolysaccharide binding protein

multiple interactions

[1,2,5,6-dibenzanthracene co-treated with fluoranthene] affects the expression of LBP mRNA

NCBI chr 3:146,953,889...146,981,032
Ensembl chr 3:146,954,015...146,981,586

G

lactate dehydrogenase A

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of LDHA mRNA

NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472

G

low density lipoprotein receptor

multiple interactions
decreases expression

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of LDLR mRNA
fluoranthene results in decreased expression of LDLR mRNA

NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580

G

leukocyte receptor cluster member 8

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of LENG8 mRNA

NCBI chr 1:70,040,785...70,052,662
Ensembl chr 1:70,040,785...70,052,488

G

leptin receptor overlapping transcript

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of LEPROT mRNA

NCBI chr 5:116,289,843...116,301,951
Ensembl chr 5:116,289,822...116,301,988

G

LFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of LFNG mRNA

NCBI chr12:14,030,551...14,038,996
Ensembl chr12:14,018,333...14,039,008

G

galectin 9

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of LGALS9 mRNA

NCBI chr10:63,907,018...63,930,224
Ensembl chr10:63,907,018...63,930,045

G

LIF, interleukin 6 family cytokine

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of LIF mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of LIF mRNA]

NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482

G

LIM and cysteine-rich domains 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of LMCD1 mRNA

NCBI chr 4:145,393,153...145,452,049
Ensembl chr 4:145,393,145...145,452,046

G

leishmanolysin like peptidase

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of LMLN mRNA

NCBI chr11:67,656,241...67,725,889
Ensembl chr11:67,658,152...67,724,243

G

lamin B1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of LMNB1 mRNA

NCBI chr18:50,175,861...50,215,210
Ensembl chr18:50,175,874...50,214,502

G

LIM domain only 4

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of LMO4 mRNA

NCBI chr 2:233,264,180...233,280,881
Ensembl chr 2:233,264,182...233,280,880

G

lysophosphatidylcholine acyltransferase 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of LPCAT3 mRNA

NCBI chr 4:157,468,397...157,509,889
Ensembl chr 4:157,468,290...157,509,880

G

lipin 1

decreases expression

fluoranthene results in decreased expression of LPIN1 mRNA

NCBI chr 6:39,309,198...39,417,034
Ensembl chr 6:39,312,748...39,417,097

G

leucine-rich repeats and immunoglobulin-like domains 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of LRIG1 mRNA

NCBI chr 4:127,130,899...127,230,956
Ensembl chr 4:127,130,898...127,231,513

G

leucine rich repeat containing 2

multiple interactions
increases expression

[1-methylanthracene co-treated with fluoranthene] results in increased expression of LRRC2 mRNA
fluoranthene results in increased expression of LRRC2 mRNA

NCBI chr 8:110,936,119...110,969,189
Ensembl chr 8:110,938,165...110,969,185

G

leucine rich repeat containing 8 VRAC subunit C

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of LRRC8C mRNA

NCBI chr14:4,223,901...4,315,590
Ensembl chr14:4,227,832...4,315,249

G

leucine rich repeat containing 8 VRAC subunit D

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of LRRC8D mRNA

NCBI chr14:4,029,971...4,134,922
Ensembl chr14:4,029,473...4,135,877

G

lanosterol synthase

decreases expression
multiple interactions

fluoranthene results in decreased expression of LSS mRNA
[1-methylanthracene co-treated with fluoranthene] results in decreased expression of LSS mRNA

NCBI chr20:12,091,138...12,118,858
Ensembl chr20:12,092,774...12,118,762

G

leucine rich adaptor protein 1-like

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of LURAP1L mRNA

NCBI chr 5:95,362,005...95,409,439
Ensembl chr 5:95,362,005...95,409,438

G

lymphocyte antigen 96

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of LY96 mRNA

NCBI chr 5:2,582,233...2,612,357
Ensembl chr 5:2,582,254...2,612,386

G

LysM domain containing 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of LYSMD3 mRNA

NCBI chr 2:11,933,787...11,939,944
Ensembl chr 2:11,933,768...11,942,961

G

lysosomal trafficking regulator

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of LYST mRNA

NCBI chr17:86,241,384...86,443,501
Ensembl chr17:86,241,384...86,443,480

G

MAF bZIP transcription factor

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of MAF mRNA

NCBI chr19:43,353,867...43,713,162
Ensembl chr19:43,360,342...43,712,365

G

MAF bZIP transcription factor F

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of MAFF mRNA

NCBI chr 7:110,912,367...110,923,711
Ensembl chr 7:110,912,499...110,923,851

G

MAF bZIP transcription factor K

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of MAFK mRNA

NCBI chr12:14,834,628...14,856,414
Ensembl chr12:14,833,984...14,837,048
Ensembl chr12:14,833,984...14,837,048

G

mitogen activated protein kinase kinase kinase 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of MAP3K2 mRNA

NCBI chr18:23,807,218...23,879,722
Ensembl chr18:23,807,218...23,871,433

G

mitogen-activated protein kinase kinase kinase 20

increases expression
multiple interactions

fluoranthene results in increased expression of MAP3K20 mRNA
[1-methylanthracene co-treated with fluoranthene] results in increased expression of MAP3K20 mRNA

NCBI chr 3:57,130,539...57,289,943
Ensembl chr 3:57,130,551...57,289,626

G

mitogen activated protein kinase 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased phosphorylation of and results in increased activity of MAPK1 protein; fluoranthene results in increased phosphorylation of and results in increased activity of MAPK1 protein

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased phosphorylation of and results in increased activity of MAPK3 protein; fluoranthene results in increased phosphorylation of and results in increased activity of MAPK3 protein

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

meiosis regulator and mRNA stability factor 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of MARF1 mRNA

NCBI chr10:888,053...932,760
Ensembl chr10:888,076...932,753

G

MARVEL domain containing 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of MARVELD1 mRNA

NCBI chr 1:240,954,050...240,958,101
Ensembl chr 1:240,954,452...240,958,384

G

microtubule associated serine/threonine kinase family member 4

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of MAST4 mRNA

NCBI chr 2:33,893,241...34,483,682
Ensembl chr 2:33,894,436...34,483,723

G

metallo-beta-lactamase domain containing 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of MBLAC2 mRNA

NCBI chr 2:11,986,075...12,028,882
Ensembl chr 2:11,986,027...12,030,950

G

membrane bound O-acyltransferase domain containing 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of MBOAT1 mRNA

NCBI chr17:34,331,413...34,445,088
Ensembl chr17:34,331,422...34,445,088

G

MCC regulator of WNT signaling pathway

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of MCC mRNA

NCBI chr18:36,794,206...37,266,237
Ensembl chr18:36,798,372...37,266,819

G

MDM2 proto-oncogene

multiple interactions

[Benzo(a)pyrene co-treated with fluoranthene] affects the expression of MDM2 mRNA

NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915

G

malic enzyme 1

multiple interactions

[Benzo(a)pyrene co-treated with fluoranthene] affects the expression of ME1 mRNA

NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304

G

mediator complex subunit 13L

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of MED13L mRNA

NCBI chr12:37,807,596...38,004,886
Ensembl chr12:37,808,285...38,004,473

G

mesenteric estrogen-dependent adipogenesis

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of MEDAG mRNA

NCBI chr12:5,613,191...5,634,583
Ensembl chr12:5,613,208...5,634,767

G

myocyte enhancer factor 2D

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of MEF2D mRNA

NCBI chr 2:173,606,054...173,635,620
Ensembl chr 2:173,606,490...173,634,457

G

Meis homeobox 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of MEIS2 mRNA

NCBI chr 3:102,742,904...102,944,833
Ensembl chr 3:102,742,900...102,949,696

G

major facilitator superfamily domain containing 9

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of MFSD9 mRNA

NCBI chr 9:43,019,611...43,039,100
Ensembl chr 9:43,019,618...43,039,176

G

MIA SH3 domain ER export factor 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of MIA2 mRNA

NCBI chr 6:76,787,508...76,885,246
Ensembl chr 6:76,787,508...76,885,211

G

mitotic deacetylase associated SANT domain protein

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of MIDEAS mRNA

NCBI chr 6:103,784,779...103,854,470
Ensembl chr 6:103,787,873...103,829,178

G

microRNA 155

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of MIR155 mRNA

NCBI chr11:23,774,654...23,774,718
Ensembl chr11:23,774,654...23,774,718

G

microRNA 22

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of MIR22 mRNA

NCBI chr10:60,307,039...60,307,133
Ensembl chr10:60,307,039...60,307,133

G

metabolism of cobalamin associated B

multiple interactions
decreases expression

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of MMAB mRNA
fluoranthene results in decreased expression of MMAB mRNA

NCBI chr12:42,159,109...42,172,518
Ensembl chr12:42,159,089...42,172,490

G

monocyte to macrophage differentiation-associated

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of MMD mRNA

NCBI chr10:75,073,278...75,101,528
Ensembl chr10:75,073,365...75,101,528

G

matrix metallopeptidase 10

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of MMP10 mRNA

NCBI chr 8:4,689,840...4,697,748
Ensembl chr 8:4,689,840...4,697,748

G

matrix metallopeptidase 13

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of MMP13 mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of MMP13 mRNA]

NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239

G

matrix metallopeptidase 28

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of MMP28 mRNA

NCBI chr10:68,241,138...68,264,866
Ensembl chr10:68,241,138...68,264,866

G

matrix metallopeptidase 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of MMP3 mRNA

NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961

G

myeloid cell nuclear differentiation antigen

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of IFI204 mRNA
[1-methylanthracene co-treated with fluoranthene] results in increased expression of MNDA mRNA

NCBI chr13:86,017,888...86,035,556
Ensembl chr13:86,017,892...86,034,201

G

MAX network transcriptional repressor

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of MNT mRNA

NCBI chr10:59,699,208...59,714,848
Ensembl chr10:59,699,585...59,714,835

G

motile sperm domain containing 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of MOSPD3 mRNA

NCBI chr12:19,095,203...19,100,303
Ensembl chr12:19,095,242...19,099,477

G

Mov10 RNA helicase

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of MOV10 mRNA

NCBI chr 2:192,292,041...192,315,142
Ensembl chr 2:192,293,470...192,315,083

G

MAGUK p55 scaffold protein 2

increases expression
multiple interactions

fluoranthene results in increased expression of MPP2 mRNA
[1-methylanthracene co-treated with fluoranthene] results in increased expression of MPP2 mRNA

NCBI chr10:87,011,434...87,043,883
Ensembl chr10:87,011,434...87,043,896

G

MPV17 mitochondrial inner membrane protein like 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of MPV17L2 mRNA

NCBI chr16:18,680,106...18,684,212
Ensembl chr16:18,681,826...18,684,212

G

mitochondrial ribosomal protein L28

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of MRPL28 mRNA

NCBI chr10:15,148,698...15,151,581
Ensembl chr10:15,148,681...15,151,581

G

mitochondrial ribosomal protein L36

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of MRPL36 mRNA

NCBI chr 1:29,965,481...29,968,896
Ensembl chr 1:29,965,317...29,968,807

G

mitochondrial ribosomal protein L51

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of MRPL51 mRNA

NCBI chr 4:157,991,756...157,994,715
Ensembl chr 4:157,992,408...157,995,414

G

methylsterol monooxygenase 1

decreases expression
multiple interactions

fluoranthene results in decreased expression of MSMO1 mRNA
[1-methylanthracene co-treated with fluoranthene] results in decreased expression of MSMO1 mRNA

NCBI chr16:24,980,680...24,997,927
Ensembl chr16:24,980,697...24,998,016

G

MTCL family member 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of MTCL3 mRNA

NCBI chr 1:28,629,036...28,701,416
Ensembl chr 1:28,620,293...28,701,796

G

methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of MTHFD2 mRNA

NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608

G

myotubularin related protein 10

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of MTMR10 mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of MTMR10 mRNA]

NCBI chr 1:117,859,355...117,910,839
Ensembl chr 1:117,859,267...117,910,849

G

mucin 2, oligomeric mucus/gel-forming

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of MUC2 mRNA

NCBI chr 1:196,799,494...196,831,740
Ensembl chr 1:196,799,517...196,831,756

G

mucin 5AC, oligomeric mucus/gel-forming

increases expression

fluoranthene results in increased expression of MUC5AC mRNA; fluoranthene results in increased expression of MUC5AC protein

NCBI chr 1:196,864,336...196,896,475
Ensembl chr 1:196,864,336...196,896,475

G

mucin 6, oligomeric mucus/gel-forming

increases expression

fluoranthene results in increased expression of MUC6 mRNA

NCBI chr 1:196,726,678...196,764,842
Ensembl chr 1:196,726,807...196,764,842

G

mevalonate diphosphate decarboxylase

decreases expression
multiple interactions

fluoranthene results in decreased expression of MVD mRNA
[1-methylanthracene co-treated with fluoranthene] results in decreased expression of MVD mRNA

NCBI chr19:50,496,366...50,506,429
Ensembl chr19:50,496,367...50,507,971

G

mevalonate kinase

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of MVK mRNA

NCBI chr12:42,141,391...42,158,893
Ensembl chr12:42,141,384...42,158,882

G

matrix remodeling associated 7

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of MXRA7 mRNA

NCBI chr10:102,003,034...102,031,428
Ensembl chr10:102,003,319...102,031,409

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of MYC mRNA

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

myosin heavy chain 6

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of MYH6 mRNA

NCBI chr15:28,418,120...28,442,316
Ensembl chr15:28,417,616...28,441,720

G

myosin light chain 12B

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of MYL12B mRNA

NCBI chr 9:110,873,855...110,888,187

G

N-acyl phosphatidylethanolamine phospholipase D

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of NAPEPLD mRNA

NCBI chr 4:13,360,532...13,398,815
Ensembl chr 4:13,361,006...13,398,748

G

nuclear prelamin A recognition factor

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of NARF mRNA

NCBI chr10:106,519,508...106,537,494
Ensembl chr10:106,519,444...106,537,486

G

neuronal calcium sensor 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of NCS1 mRNA

NCBI chr 3:14,523,220...14,568,829
Ensembl chr 3:14,523,220...14,568,829

G

nudE neurodevelopment protein 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of NDE1 mRNA

NCBI chr10:839,788...883,946
Ensembl chr10:839,788...883,869

G

nudE neurodevelopment protein 1-like 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of NDEL1 mRNA

NCBI chr10:53,505,628...53,582,025
Ensembl chr10:53,516,491...53,570,907

G

N-myc downstream regulated 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of NDRG1 mRNA

NCBI chr 7:98,684,487...98,725,869
Ensembl chr 7:98,684,487...98,725,880

G

NEDD4 like E3 ubiquitin protein ligase

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of NEDD4L mRNA

NCBI chr18:58,393,759...58,726,709
Ensembl chr18:58,393,509...58,723,137

G

neuralized E3 ubiquitin protein ligase 3

increases expression
multiple interactions

fluoranthene results in increased expression of NEURL3 mRNA
[1-methylanthracene co-treated with fluoranthene] results in increased expression of NEURL3 mRNA

NCBI chr 9:38,494,486...38,503,352
Ensembl chr 9:38,494,489...38,502,649

G

NFE2 like bZIP transcription factor 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of NFE2L2 mRNA

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear factor, interleukin 3 regulated

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of NFIL3 mRNA

NCBI chr17:12,280,499...12,295,728
Ensembl chr17:12,280,484...12,295,858

G

nuclear factor kappa B subunit 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of NFKB2 mRNA
[naphthalene co-treated with phenanthrene co-treated with anthracene co-treated with fluoranthene co-treated with pyrene] results in increased expression of NFKB2 protein

PMID:28329830 PMID:30980910

NCBI chr 1:245,164,586...245,173,225
Ensembl chr 1:245,165,950...245,173,213

G

NFKB inhibitor epsilon

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of NFKBIE mRNA

NCBI chr 9:15,443,600...15,450,437
Ensembl chr 9:15,436,941...15,450,437

G

NFKB inhibitor zeta

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of NFKBIZ mRNA

NCBI chr11:44,782,676...44,810,722
Ensembl chr11:44,782,676...44,810,723

G

nuclear transcription factor Y subunit beta

decreases expression

fluoranthene results in decreased expression of NFYB mRNA

NCBI chr 7:20,964,988...20,980,569
Ensembl chr 7:20,964,993...20,980,565

G

NHERF family PDZ scaffold protein 1

decreases expression

fluoranthene results in decreased expression of NHERF1 mRNA

NCBI chr10:100,403,189...100,420,290
Ensembl chr10:100,403,069...100,420,598

G

NHS actin remodeling regulator

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of NHS mRNA

NCBI chr X:32,553,300...32,892,961
Ensembl chr X:32,552,026...32,889,992

G

Sodium/potassium transporting ATPase interacting 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of NKAIN1 mRNA

NCBI chr 5:142,747,702...142,792,665
Ensembl chr 5:142,747,505...142,791,863

G

NMD3 ribosome export adaptor

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of NMD3 mRNA

NCBI chr 2:154,012,973...154,038,466
Ensembl chr 2:154,013,020...154,039,259

G

nucleolar protein 8

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of NOL8 mRNA

NCBI chr17:14,990,394...15,013,784
Ensembl chr17:14,990,417...15,013,848

G

NOP58 ribonucleoprotein

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of NOP58 mRNA

NCBI chr 9:61,120,939...61,144,810
Ensembl chr 9:61,120,929...61,144,810

G

nitric oxide synthase 3

multiple interactions
increases expression

1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [fluoranthene results in increased expression of NOS3 mRNA]; 1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole inhibits the reaction [fluoranthene results in increased expression of NOS3 protein]; nickel chloride inhibits the reaction [fluoranthene results in increased expression of NOS3 protein]; Proadifen inhibits the reaction [fluoranthene results in increased expression of NOS3 protein]
fluoranthene results in increased expression of NOS3 mRNA; fluoranthene results in increased expression of NOS3 protein

NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166

G

NAD(P)H quinone dehydrogenase 1

multiple interactions
increases expression

[1,2,5,6-dibenzanthracene co-treated with fluoranthene] affects the expression of NQO1 mRNA; [Benzo(a)pyrene co-treated with fluoranthene] affects the expression of NQO1 mRNA
fluoranthene results in increased expression of NQO1 mRNA
[1-methylanthracene co-treated with fluoranthene] results in increased expression of NQO1 mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of NQO1 mRNA]

PMID:18711122 PMID:28329830

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

N-ribosyldihydronicotinamide:quinone dehydrogenase 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of NQO2 mRNA

NCBI chr17:30,909,482...30,938,725
Ensembl chr17:30,909,187...30,938,320

G

nuclear receptor subfamily 1, group D, member 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of NR1D1 mRNA

NCBI chr10:83,728,348...83,735,562
Ensembl chr10:83,728,318...83,735,705

G

nuclear receptor subfamily 1, group D, member 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of NR1D2 mRNA

NCBI chr15:7,524,257...7,550,553
Ensembl chr15:7,524,257...7,550,553

G

nuclear receptor subfamily 1, group H, member 4

increases expression
multiple interactions

fluoranthene results in increased expression of NR1H4 mRNA
[1-methylanthracene co-treated with fluoranthene] results in increased expression of NR1H4 mRNA

NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions

fluoranthene binds to and results in increased activity of NR1I2 protein

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

nuclear receptor subfamily 1, group I, member 3

increases activity
multiple interactions
increases expression

fluoranthene results in increased activity of NR1I3 protein
[Benzo(a)pyrene co-treated with fluoranthene] inhibits the reaction [pyrene results in increased expression of NR1I3 mRNA]; [Benzo(a)pyrene co-treated with pyrene] inhibits the reaction [fluoranthene results in increased expression of NR1I3 mRNA]; Benzo(a)pyrene inhibits the reaction [fluoranthene results in increased expression of NR1I3 mRNA]; fluoranthene inhibits the reaction [pyrene results in increased expression of NR1I3 mRNA]; pyrene inhibits the reaction [fluoranthene results in increased expression of NR1I3 mRNA]

PMID:28927721 PMID:33249052

NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906

G

nuclear receptor subfamily 3, group C, member 1

increases expression
multiple interactions

fluoranthene results in increased expression of NR3C1 mRNA
[1-methylanthracene co-treated with fluoranthene] results in increased expression of NR3C1 mRNA

NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375

G

nuclear receptor subfamily 4, group A, member 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of NR4A1 mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of NR4A1 mRNA]

NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297

G

nuclear receptor subfamily 4, group A, member 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of NR4A2 mRNA

NCBI chr 3:41,689,847...41,707,036
Ensembl chr 3:41,689,851...41,697,877

G

nuclear receptor subfamily 4, group A, member 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of NR4A3 mRNA

NCBI chr 5:62,361,588...62,401,489
Ensembl chr 5:62,361,822...62,402,733

G

neuregulin 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of NRG1 mRNA

NCBI chr16:59,250,658...60,304,519
Ensembl chr16:59,250,854...60,296,884

G

NAD(P) dependent steroid dehydrogenase-like

decreases expression
multiple interactions

fluoranthene results in decreased expression of NSDHL mRNA
[1-methylanthracene co-treated with fluoranthene] results in decreased expression of NSDHL mRNA

NCBI chr X:150,775,034...150,807,161
Ensembl chr X:150,775,080...150,807,142

G

5'-nucleotidase domain containing 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of NT5DC3 mRNA

NCBI chr 7:21,190,554...21,247,374
Ensembl chr 7:21,190,554...21,247,374

G

nudix hydrolase 16 like 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of NUDT16L1 mRNA

NCBI chr10:10,636,174...10,638,090
Ensembl chr10:10,636,174...10,688,370

G

nucleoporin 58

multiple interactions

[1,2,5,6-dibenzanthracene co-treated with fluoranthene] affects the expression of NUP58 mRNA

NCBI chr15:34,358,170...34,407,160
Ensembl chr15:34,358,277...34,407,060

G

nuclear protein 1, transcriptional regulator

multiple interactions

[1,2,5,6-dibenzanthracene co-treated with fluoranthene] affects the expression of NUPR1 mRNA

NCBI chr 1:181,213,292...181,215,327
Ensembl chr 1:181,213,368...181,215,281

G

ornithine decarboxylase antizyme 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of OAZ2 mRNA

NCBI chr 8:66,199,694...66,213,513
Ensembl chr 8:66,199,706...66,231,453

G

opioid growth factor receptor-like 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of OGFRL1 mRNA

NCBI chr 9:25,828,865...25,842,424
Ensembl chr 9:25,828,869...25,842,352

G

oxidized low density lipoprotein receptor 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of OLR1 mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of OLR1 mRNA]

NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523

G

OMA1 zinc metallopeptidase

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of OMA1 mRNA

NCBI chr 5:118,083,728...118,136,980
Ensembl chr 5:118,083,728...118,136,980

G

olfactory receptor family 51 subfamily I member 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of OR51I2 mRNA

NCBI chr 1:158,513,673...158,514,611
Ensembl chr 1:158,513,673...158,514,611

G

ORMDL sphingolipid biosynthesis regulator 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of ORMDL1 mRNA

NCBI chr 9:48,243,365...48,253,316
Ensembl chr 9:48,237,572...48,253,211

G

ORMDL sphingolipid biosynthesis regulator 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of ORMDL2 mRNA

NCBI chr 7:1,247,869...1,250,999
Ensembl chr 7:1,246,479...1,250,907

G

oxidative stress responsive serine-rich 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of OSER1 mRNA

NCBI chr 3:152,066,975...152,085,180
Ensembl chr 3:152,066,975...152,085,149

G

oxidative stress induced growth inhibitor 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of OSGIN1 mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of OSGIN1 mRNA]

NCBI chr19:47,471,750...47,500,517
Ensembl chr19:47,492,171...47,500,516

G

oncostatin M receptor

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of OSMR mRNA

NCBI chr 2:55,907,119...55,961,373
Ensembl chr 2:55,907,132...55,961,262

G

prolyl 4-hydroxylase subunit alpha 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of P4HA2 mRNA

NCBI chr10:38,243,136...38,271,983
Ensembl chr10:38,243,139...38,287,314

G

progestin and adipoQ receptor family member 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of PAQR3 mRNA

NCBI chr14:12,462,568...12,484,999
Ensembl chr14:12,462,563...12,479,994

G

poly (ADP-ribose) polymerase 1

increases cleavage

fluoranthene results in increased cleavage of PARP1 protein

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

prolyl-tRNA synthetase 2, mitochondrial

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of PARS2 mRNA

NCBI chr 5:121,433,993...121,439,158
Ensembl chr 5:121,434,096...121,439,154

G

pro-apoptotic WT1 regulator

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of PAWR mRNA

NCBI chr 7:43,645,028...43,725,033
Ensembl chr 7:43,645,084...43,725,028

G

pterin-4 alpha-carbinolamine dehydratase 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of PCBD2 mRNA

NCBI chr17:8,845,161...8,896,343
Ensembl chr17:8,845,084...8,910,539

G

pyruvate dehydrogenase kinase 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of PDK1 mRNA

NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:56,705,871...56,733,038

G

period circadian regulator 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of PER1 mRNA

NCBI chr10:53,800,126...53,814,963
Ensembl chr10:53,805,535...53,814,431

G

period circadian regulator 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of PER2 mRNA

NCBI chr 9:92,007,289...92,049,551
Ensembl chr 9:92,007,296...92,049,459

G

6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1

multiple interactions

[Benzo(a)pyrene co-treated with fluoranthene] affects the expression of PFKFB1 mRNA

NCBI chr X:19,508,522...19,562,165
Ensembl chr X:19,508,546...19,562,182

G

phosphofructokinase, liver type

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of PFKL mRNA

NCBI chr20:10,664,285...10,686,324
Ensembl chr20:10,664,272...10,686,315

G

phosphoglycerate mutase 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of PGAM1 mRNA

NCBI chr 1:240,723,832...240,731,443
Ensembl chr 1:240,723,920...240,738,452

G

phosphoglucomutase 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of PGM2 mRNA

NCBI chr14:44,166,314...44,199,828
Ensembl chr14:44,164,425...44,199,967

G

phosphoglycolate phosphatase

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of PGP mRNA

NCBI chr10:13,495,232...13,497,858
Ensembl chr10:13,494,291...13,497,858

G

pleckstrin homology-like domain, family A, member 1

multiple interactions
increases expression

[1-methylanthracene co-treated with fluoranthene] results in increased expression of PHLDA1 mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of PHLDA1 mRNA]
fluoranthene results in increased expression of PHLDA1 mRNA

NCBI chr 7:46,967,433...46,969,637
Ensembl chr 7:46,967,409...46,969,861

G

phosphatidylinositol 4-kinase type 2 beta

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of PI4K2B mRNA

NCBI chr14:58,221,790...58,248,716
Ensembl chr14:58,220,437...58,248,673

G

Pim-3 proto-oncogene, serine/threonine kinase

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of PIM3 mRNA

NCBI chr 7:119,953,377...119,956,587
Ensembl chr 7:119,953,175...119,956,587

G

phosphatidylinositol-5-phosphate 4-kinase type 2 beta

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of PIP4K2B mRNA

NCBI chr10:82,706,016...82,734,938
Ensembl chr10:82,701,098...82,734,938

G

phosphatidylinositol transfer protein, cytoplasmic 1

increases expression
multiple interactions

fluoranthene results in increased expression of PITPNC1 mRNA
[1-methylanthracene co-treated with fluoranthene] results in increased expression of PITPNC1 mRNA

NCBI chr10:92,163,558...92,428,971
Ensembl chr10:92,167,196...92,429,297

G

phospholipase A2 group 4A

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of PLA2G4A mRNA; [1-methylanthracene co-treated with fluoranthene] results in increased phosphorylation of and results in increased activity of PLA2G4A protein

PMID:28329830 PMID:30690640

NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266

G

plasminogen activator, urokinase receptor

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of PLAUR mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of PLAUR mRNA]

NCBI chr 1:80,053,440...80,068,384
Ensembl chr 1:80,050,324...80,068,595

G

phospholipase C, delta 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of PLCD3 mRNA

NCBI chr10:88,026,707...88,048,080
Ensembl chr10:88,026,740...88,048,296

G

phospholipase C-like 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of PLCL2 mRNA

NCBI chr 9:3,292,564...3,477,009
Ensembl chr 9:3,292,695...3,477,009

G

pleckstrin homology domain containing A2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of PLEKHA2 mRNA

NCBI chr16:66,938,684...67,000,661
Ensembl chr16:66,939,109...66,999,395

G

pleckstrin homology and FYVE domain containing 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of PLEKHF1 mRNA

NCBI chr 1:90,908,304...90,915,862
Ensembl chr 1:90,904,742...90,915,820

G

polo-like kinase 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of PLK2 mRNA

NCBI chr 2:41,969,176...41,974,945
Ensembl chr 2:41,969,176...41,974,947

G

polo-like kinase 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of PLK3 mRNA

NCBI chr 5:130,607,142...130,612,317
Ensembl chr 5:130,607,142...130,612,317

G

phospholipid phosphatase 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of PPAP2A mRNA

NCBI chr 2:44,439,002...44,500,430
Ensembl chr 2:44,438,994...44,501,268

G

PML nuclear body scaffold

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of PML mRNA

NCBI chr 8:58,627,347...58,661,927
Ensembl chr 8:58,628,837...58,658,971

G

proline-rich nuclear receptor coactivator 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of PNRC2 mRNA

NCBI chr 5:148,103,966...148,106,950
Ensembl chr 5:148,095,699...148,107,242
Ensembl chr 5:148,095,699...148,107,242

G

RNA polymerase II subunit D

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of POLR2D mRNA

NCBI chr18:23,418,097...23,425,228
Ensembl chr18:23,418,097...23,425,228

G

RNA polymerase III subunit D

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of POLR3D mRNA

NCBI chr15:45,511,587...45,516,256
Ensembl chr15:45,511,589...45,516,353

G

RNA polymerase III subunit G

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of POLR3G mRNA

NCBI chr 2:11,945,215...11,986,125
Ensembl chr 2:11,945,217...11,986,125

G

protein O-linked mannose N-acetylglucosaminyltransferase 2 (beta 1,4-)

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of POMGNT2 mRNA

NCBI chr 8:121,645,106...121,660,761
Ensembl chr 8:121,644,970...121,660,757

G

protein-O-mannose kinase

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of POMK mRNA

NCBI chr16:66,085,569...66,101,360
Ensembl chr16:66,088,000...66,098,388

G

peter pan homolog

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of PPAN mRNA

NCBI chr 8:19,423,908...19,427,941
Ensembl chr 8:19,423,961...19,427,938

G

peroxisome proliferator-activated receptor delta

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of PPARD mRNA

NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968

G

peroxisome proliferator-activated receptor gamma

multiple interactions

fluoranthene binds to and results in increased activity of PPARG protein

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

protein phosphatase 1, regulatory subunit 15A

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of PPP1R15A mRNA

NCBI chr 1:96,000,053...96,003,128
Ensembl chr 1:96,000,058...96,003,171

G

protein phosphatase 1, regulatory subunit 3B

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of PPP1R3B mRNA

NCBI chr16:56,830,011...56,842,395
Ensembl chr16:56,829,660...56,842,406

G

PPARG related coactivator 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of PPRC1 mRNA

NCBI chr 1:244,901,985...244,918,587
Ensembl chr 1:244,902,179...244,918,587

G

PRELI domain containing 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of PRELID1 mRNA

NCBI chr17:9,305,349...9,308,389
Ensembl chr17:9,305,361...9,308,407

G

proline and arginine rich end leucine rich repeat protein

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of PRELP mRNA

NCBI chr13:45,368,407...45,391,480
Ensembl chr13:45,370,533...45,380,270

G

protein kinase cAMP-activated catalytic subunit alpha

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of PRKACA mRNA

NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430

G

prostaglandin reductase 1

multiple interactions

[1,2,5,6-dibenzanthracene co-treated with fluoranthene] affects the expression of PTGR1 mRNA; [Benzo(a)pyrene co-treated with fluoranthene] affects the expression of PTGR1 mRNA

NCBI chr 5:73,784,000...73,802,624
Ensembl chr 5:73,784,009...73,802,666

G

prostaglandin-endoperoxide synthase 2

increases expression
multiple interactions

fluoranthene results in increased expression of PTGS2 mRNA
[1-methylanthracene co-treated with fluoranthene] promotes the reaction [Benzo(a)pyrene results in increased expression of PTGS2 mRNA]; [1-methylanthracene co-treated with fluoranthene] results in increased expression of PTGS2 mRNA; [1-methylanthracene co-treated with fluoranthene] results in increased expression of PTGS2 protein; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of PTGS2 mRNA]

PMID:28329830 PMID:29170806 PMID:30690640

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

protein tyrosine phosphatase, non-receptor type 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of PTPN2 mRNA

NCBI chr18:61,229,012...61,294,662
Ensembl chr18:61,229,014...61,294,627

G

protein tyrosine phosphatase, non-receptor type 22

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of PTPN22 mRNA

NCBI chr 2:191,366,761...191,414,782
Ensembl chr 2:191,366,808...191,414,779

G

protein tyrosine phosphatase, receptor type, E

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of PTPRE mRNA

NCBI chr 1:190,344,331...190,494,815
Ensembl chr 1:190,344,401...190,489,534

G

pentraxin 3

multiple interactions
increases expression

[1-methylanthracene co-treated with fluoranthene] results in increased expression of PTX3 mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of PTX3 mRNA]
fluoranthene results in increased expression of PTX3 mRNA

NCBI chr 2:150,487,513...150,493,323
Ensembl chr 2:150,487,513...150,493,323

G

PVR cell adhesion molecule

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of PVR mRNA

NCBI chr 1:79,561,294...79,576,700
Ensembl chr 1:79,546,879...79,576,715

G

PX domain containing 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of PXDC1 mRNA

NCBI chr17:30,275,998...30,304,971
Ensembl chr17:30,276,377...30,304,973

G

peroxidasin

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of PXDN mRNA

NCBI chr 6:46,580,749...46,658,345
Ensembl chr 6:46,580,761...46,658,345

G

glutaminyl-peptide cyclotransferase-like

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of QPCTL mRNA

NCBI chr 1:78,786,730...78,797,956
Ensembl chr 1:78,788,739...78,797,811

G

queuine tRNA-ribosyltransferase accessory subunit 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of QTRT2 mRNA

NCBI chr11:56,806,417...56,837,239
Ensembl chr11:56,806,385...56,837,228

G

RAB1B, member RAS oncogene family

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of RAB1B mRNA

NCBI chr 1:202,405,759...202,413,850
Ensembl chr 1:202,405,759...202,413,868
Ensembl chr X:202,405,759...202,413,868

G

RAB20, member RAS oncogene family

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of RAB20 mRNA

NCBI chr16:78,019,337...78,043,529
Ensembl chr16:78,019,337...78,043,529

G

RAB29, member RAS oncogene family

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of RAB29 mRNA

NCBI chr13:43,307,757...43,313,420
Ensembl chr13:43,307,775...43,313,417

G

RAB3D, member RAS oncogene family

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of RAB3D mRNA

NCBI chr 8:20,438,622...20,449,269
Ensembl chr 8:20,439,294...20,449,185

G

Rab geranylgeranyltransferase subunit beta

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of RABGGTB mRNA

NCBI chr 2:242,844,758...242,850,951
Ensembl chr 2:242,844,762...242,851,050

G

RAN binding protein 9

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of RANBP9 mRNA

NCBI chr17:21,220,807...21,303,009
Ensembl chr17:21,220,618...21,303,004

G

Rap guanine nucleotide exchange factor 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of RAPGEF2 mRNA

NCBI chr 2:164,207,513...164,322,157
Ensembl chr 2:164,207,513...164,244,247

G

RasGEF domain family, member 1B

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of RASGEF1B mRNA

NCBI chr14:9,859,512...10,380,044
Ensembl chr14:9,860,247...10,379,741

G

Ras association domain family member 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of RASSF1 mRNA

NCBI chr 8:108,225,023...108,236,164
Ensembl chr 8:108,225,023...108,236,164

G

Ras association domain family member 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of RASSF3 mRNA

NCBI chr 7:56,935,888...57,000,554
Ensembl chr 7:56,935,973...57,000,553

G

Ras association domain family member 8

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of RASSF8 mRNA

NCBI chr 4:178,716,110...178,798,042
Ensembl chr 4:178,719,992...178,796,690

G

RNA binding motif protein 33

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of RBM33 mRNA

NCBI chr 4:6,980,807...7,088,334
Ensembl chr 4:6,983,970...7,089,918

G

retinol dehydrogenase 11

decreases expression
multiple interactions

fluoranthene results in decreased expression of RDH11 mRNA
[1-methylanthracene co-treated with fluoranthene] results in decreased expression of RDH11 mRNA

NCBI chr 6:97,979,377...97,995,252
Ensembl chr 6:97,979,378...97,995,252

G

reversion-inducing-cysteine-rich protein with kazal motifs

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of RECK mRNA

NCBI chr 5:58,102,961...58,169,516
Ensembl chr 5:58,102,981...58,169,502

G

receptor accessory protein 6

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of REEP6 mRNA

NCBI chr 7:9,373,927...9,380,845
Ensembl chr 7:9,373,927...9,380,597

G

RELB proto-oncogene, NF-kB subunit

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of RELB mRNA

NCBI chr 1:79,257,738...79,285,490
Ensembl chr 1:79,257,725...79,285,507

G

refilin B

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of RFLNB mRNA

NCBI chr10:60,893,693...60,899,970
Ensembl chr10:60,893,713...60,899,976

G

rhomboid domain containing 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of RHBDD2 mRNA

NCBI chr12:21,043,605...21,054,305
Ensembl chr12:21,043,608...21,054,289

G

rhomboid 5 homolog 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of RHBDF2 mRNA

NCBI chr10:101,833,157...101,860,283
Ensembl chr10:101,833,157...101,860,283

G

ras homolog family member B

decreases expression

fluoranthene results in decreased expression of RHOB mRNA

NCBI chr 6:31,363,752...31,365,926
Ensembl chr 6:31,363,548...31,366,108

G

rhophilin, Rho GTPase binding protein 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of RHPN2 mRNA

NCBI chr 1:87,991,143...88,051,895
Ensembl chr 1:87,991,144...88,051,902

G

receptor-interacting serine-threonine kinase 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of RIPK2 mRNA

NCBI chr 5:29,630,806...29,662,804
Ensembl chr 5:29,631,570...29,662,657

G

Rho family GTPase 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of RND1 mRNA

NCBI chr 7:129,821,311...129,828,385
Ensembl chr 7:129,821,311...129,828,399

G

Rho family GTPase 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of RND3 mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of RND3 mRNA]

NCBI chr 3:35,571,929...35,589,283
Ensembl chr 3:35,571,143...35,589,327

G

ring finger protein 125

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of RNF125 mRNA

NCBI chr18:12,254,066...12,275,719
Ensembl chr18:12,253,852...12,275,983

G

ring finger protein 19B

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of RNF19B mRNA

NCBI chr 5:141,406,085...141,431,376
Ensembl chr 5:141,406,118...141,431,380

G

ring finger protein 217

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of RNF217 mRNA

NCBI chr 1:26,016,668...26,108,736
Ensembl chr 1:26,015,728...26,108,736

G

RAR-related orphan receptor A

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of RORA mRNA

NCBI chr 8:69,301,635...70,034,741
Ensembl chr 8:69,301,733...70,025,931

G

ribonuclease P/MRP subunit p38

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of RPP38 mRNA

NCBI chr17:74,914,066...74,917,742
Ensembl chr17:74,908,932...74,927,431

G

RRAD, Ras related glycolysis inhibitor and calcium channel regulator

multiple interactions

[1,2,5,6-dibenzanthracene co-treated with fluoranthene] affects the expression of RRAD mRNA; [Benzo(a)pyrene co-treated with fluoranthene] affects the expression of RRAD mRNA

NCBI chr19:354,184...357,424
Ensembl chr19:354,198...357,417

G

RUN and SH3 domain containing 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of RUSC2 mRNA

NCBI chr 5:57,628,397...57,675,524
Ensembl chr 5:57,629,904...57,675,524

G

S100 calcium binding protein A16

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of S100A16 mRNA

NCBI chr 2:176,016,405...176,022,117
Ensembl chr 2:176,016,268...176,022,117

G

S100 calcium-binding protein A4

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of S100A4 mRNA

NCBI chr 2:176,090,951...176,093,258
Ensembl chr 2:176,091,804...176,093,254

G

spermidine/spermine N1-acetyl transferase 1

multiple interactions

[Benzo(a)pyrene co-treated with fluoranthene] affects the expression of SAT1 mRNA

NCBI chr X:40,158,354...40,161,641
Ensembl chr X:40,157,046...40,196,813

G

strawberry notch homolog 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of SBNO2 mRNA

NCBI chr 7:9,605,572...9,649,529
Ensembl chr 7:9,605,627...9,649,527

G

sterol-C5-desaturase

decreases expression

fluoranthene results in decreased expression of SC5D mRNA

NCBI chr 8:42,629,649...42,641,257
Ensembl chr 8:42,632,672...42,641,273

G

secretory carrier membrane protein 5

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of SCAMP5 mRNA

NCBI chr 8:57,845,831...57,884,516
Ensembl chr 8:57,846,659...57,872,027

G

scleraxis bHLH transcription factor

multiple interactions
decreases expression

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of SCX mRNA
fluoranthene results in decreased expression of SCX mRNA

NCBI chr 7:108,176,608...108,178,626
Ensembl chr 7:108,176,608...108,178,626

G

SDA1 domain containing 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of SDAD1 mRNA

NCBI chr14:15,741,489...15,768,271
Ensembl chr14:15,741,434...15,771,066

G

SDE2 telomere maintenance homolog

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of SDE2 mRNA

NCBI chr13:92,578,843...92,595,142
Ensembl chr13:92,578,874...92,595,140

G

SEC16 homolog A, endoplasmic reticulum export factor

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of SEC16A mRNA

NCBI chr 3:9,229,687...9,264,837
Ensembl chr 3:9,229,687...9,264,273

G

Sec23 homolog A, COPII coat complex component

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of SEC23A mRNA

NCBI chr 6:76,658,793...76,706,125
Ensembl chr 6:76,658,427...76,706,035

G

SEC24 homolog A, COPII coat complex component

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of SEC24A mRNA

NCBI chr10:35,946,901...36,024,353
Ensembl chr10:35,947,031...36,024,353

G

semaphorin 7A (John Milton Hagen blood group)

decreases expression

fluoranthene results in decreased expression of SEMA7A mRNA

NCBI chr 8:58,348,448...58,370,536
Ensembl chr 8:58,348,448...58,370,536

G

SUMO peptidase family member, NEDD8 specific

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of SENP8 mRNA

NCBI chr 8:60,135,446...60,148,836
Ensembl chr 8:60,121,714...60,148,928

G

selenophosphate synthetase 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of SEPHS2 mRNA

NCBI chr 1:181,893,146...181,895,464
Ensembl chr 1:181,892,599...181,895,497

G

serine (or cysteine) peptidase inhibitor, clade A, member 3N

multiple interactions

[Benzo(a)pyrene co-treated with fluoranthene] affects the expression of SERPINA3 mRNA

NCBI chr 6:123,323,623...123,331,181
Ensembl chr 6:123,323,629...123,332,433

G

serpin family B member 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of SERPINB2 mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of SERPINB2 mRNA]

NCBI chr13:23,537,312...23,551,823
Ensembl chr13:23,541,400...23,550,408

G

serpin family D member 1

multiple interactions

[1,2,5,6-dibenzanthracene co-treated with fluoranthene] affects the expression of SERPIND1 mRNA

NCBI chr11:83,664,517...83,675,593
Ensembl chr11:83,664,518...83,675,519

G

sestrin 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of SESN1 mRNA

NCBI chr20:45,294,876...45,387,698
Ensembl chr20:45,294,871...45,387,697

G

sestrin 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of SESN2 mRNA

NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260

G

serum/glucocorticoid regulated kinase 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of SGK1 mRNA

NCBI chr 1:22,980,257...23,098,122
Ensembl chr 1:22,980,261...23,098,283

G

SH3 domain binding glutamate-rich protein like 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of SH3BGRL3 mRNA

NCBI chr 5:146,354,152...146,355,525
Ensembl chr 5:146,354,152...146,355,331

G

sigma non-opioid intracellular receptor 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of SIGMAR1 mRNA

NCBI chr 5:56,904,155...56,907,012
Ensembl chr 5:56,904,159...56,907,017

G

SKI-like proto-oncogene

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of SKIL mRNA

NCBI chr 2:112,247,047...112,275,176
Ensembl chr 2:112,247,051...112,275,080

G

src-like adaptor

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of SLA mRNA

NCBI chr 7:98,534,431...98,584,810
Ensembl chr 7:98,535,368...98,584,648

G

solute carrier family 12 member 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of SLC12A2 mRNA

NCBI chr18:51,348,282...51,416,448
Ensembl chr18:51,348,302...51,416,440

G

solute carrier family 16 member 1

multiple interactions

[1,2,5,6-dibenzanthracene co-treated with fluoranthene] affects the expression of SLC16A1 mRNA; [Benzo(a)pyrene co-treated with fluoranthene] affects the expression of SLC16A1 mRNA

NCBI chr 2:192,123,755...192,144,617
Ensembl chr 2:192,124,289...192,144,611

G

solute carrier family 16 member 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of SLC16A2 mRNA

NCBI chr X:68,725,365...68,848,572
Ensembl chr X:68,723,261...68,848,771

G

solute carrier family 18 member B1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of SLC18B1 mRNA

NCBI chr 1:21,628,235...21,670,807
Ensembl chr 1:21,628,237...21,670,684

G

solute carrier family 1 member 4

increases expression
multiple interactions

fluoranthene results in increased expression of SLC1A4 mRNA
[1-methylanthracene co-treated with fluoranthene] results in increased expression of SLC1A4 mRNA

NCBI chr14:94,530,801...94,560,190
Ensembl chr14:94,529,084...94,560,418

G

solute carrier family 20 member 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of SLC20A1 mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of SLC20A1 mRNA]

NCBI chr 3:116,427,095...116,441,049
Ensembl chr 3:116,427,098...116,441,051

G

solute carrier family 22, member 23

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of SLC22A23 mRNA

NCBI chr17:30,544,106...30,709,790
Ensembl chr17:30,544,106...30,709,790

G

solute carrier family 25 member 13

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of SLC25A13 mRNA

NCBI chr 4:34,179,224...34,361,912
Ensembl chr 4:34,179,224...34,361,902

G

solute carrier family 25 member 23

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of SLC25A23 mRNA

NCBI chr 9:1,882,636...1,898,369
Ensembl chr 9:1,882,621...1,898,561

G

solute carrier family 25 member 25

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of SLC25A25 mRNA

NCBI chr 3:15,708,702...15,742,195
Ensembl chr 3:15,708,703...15,742,216

G

solute carrier family 25, member 30

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of SLC25A30 mRNA

NCBI chr15:51,076,998...51,099,613
Ensembl chr15:51,077,002...51,099,613

G

solute carrier family 25 member 37

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of SLC25A37 mRNA

NCBI chr15:44,534,280...44,576,697
Ensembl chr15:44,536,727...44,577,199

G

solute carrier family 29 member 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of SLC29A3 mRNA

NCBI chr20:28,645,265...28,685,388
Ensembl chr20:28,647,391...28,685,388

G

solute carrier family 30 member 4

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of SLC30A4 mRNA

NCBI chr 3:109,753,270...109,775,306
Ensembl chr 3:109,753,273...109,775,306

G

solute carrier family 31 member 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of SLC31A2 mRNA

NCBI chr 5:75,738,008...75,748,542
Ensembl chr 5:75,738,024...75,748,542

G

solute carrier family 35 member D2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of SLC35D2 mRNA

NCBI chr17:987,899...1,019,747
Ensembl chr17:988,157...1,019,743

G

solute carrier family 35, member G1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of SLC35G1 mRNA

NCBI chr 1:236,163,593...236,172,115
Ensembl chr 1:236,163,175...236,170,262

G

solute carrier family 38, member 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of SLC38A2 mRNA

NCBI chr 7:127,851,267...127,863,482
Ensembl chr 7:127,851,267...127,863,436

G

solute carrier family 38, member 6

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of SLC38A6 mRNA

NCBI chr 6:91,987,652...92,076,416
Ensembl chr 6:91,987,672...92,049,935

G

solute carrier family 3 member 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of SLC3A2 mRNA

NCBI chr 1:205,604,468...205,618,931
Ensembl chr 1:205,604,468...205,618,931

G

solute carrier family 7 member 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of SLC7A1 mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of SLC7A1 mRNA]

NCBI chr12:6,628,288...6,703,849
Ensembl chr12:6,628,007...6,703,849

G

solute carrier family 7 member 11

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of SLC7A11 mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of SLC7A11 mRNA]

NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536

G

SMAD family member 3

multiple interactions

[Benzo(a)pyrene co-treated with fluoranthene] affects the expression of SMAD3 mRNA
[1-methylanthracene co-treated with fluoranthene] results in increased expression of SMAD3 mRNA

PMID:18711122 PMID:28329830

NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960

G

SMAD family member 6

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of SMAD6 mRNA

NCBI chr 8:64,450,114...64,519,673
Ensembl chr 8:64,450,114...64,519,763

G

small integral membrane protein 11

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of SMIM11 mRNA

NCBI chr11:31,533,257...31,543,002
Ensembl chr11:31,532,764...31,543,002

G

small integral membrane protein 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of SMIM3 mRNA

NCBI chr18:53,930,019...53,982,339
Ensembl chr18:53,930,020...53,957,416

G

smoothelin-like 2

decreases expression
multiple interactions

fluoranthene results in decreased expression of SMTNL2 mRNA
[1-methylanthracene co-treated with fluoranthene] results in decreased expression of SMTNL2 mRNA

NCBI chr10:57,008,322...57,029,505
Ensembl chr10:57,008,327...57,029,505

G

snail family transcriptional repressor 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of SNAI2 mRNA

NCBI chr11:86,182,788...86,186,203
Ensembl chr11:86,181,909...86,186,200

G

SNAP-associated protein

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of SNAPIN mRNA

NCBI chr 2:175,971,575...175,974,164
Ensembl chr 2:175,971,257...175,974,231

G

small nucleolar RNA, H/ACA box 23

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of SNORA23 mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of SNORA23 mRNA]

NCBI chr 1:164,091,024...164,091,206
Ensembl chr 1:164,091,024...164,091,206

G

small nucleolar RNA, H/ACA box 62

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of SNORA62 mRNA

NCBI chr 8:119,853,958...119,854,106
Ensembl chr 8:119,853,958...119,854,106

G

small nucleolar RNA, H/ACA box 75

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of SNORA75 mRNA

NCBI chr 9:87,000,248...87,000,384
Ensembl chr 9:87,000,248...87,000,384

G

small nucleolar RNA, C/D box 104

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of SNORD104 mRNA

NCBI chr10:91,435,313...91,435,382
Ensembl chr10:91,435,313...91,435,382

G

sorting nexin 7

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of SNX7 mRNA

NCBI chr 2:205,843,164...205,927,737
Ensembl chr 2:205,842,837...205,927,763

G

suppressor of cytokine signaling 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of SOCS3 mRNA

NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787

G

sorbin and SH3 domain containing 3

multiple interactions
decreases expression

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of SORBS3 mRNA
fluoranthene results in decreased expression of SORBS3 mRNA

NCBI chr15:45,252,921...45,284,758
Ensembl chr15:45,253,379...45,284,758

G

SRY-box transcription factor 4

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of SOX4 mRNA

NCBI chr17:35,667,809...35,672,515
Ensembl chr17:35,667,537...35,673,665

G

Sp3 transcription factor

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of SP3 mRNA

NCBI chr 3:57,811,855...57,857,150
Ensembl chr 3:57,812,075...57,860,342

G

secreted phosphoprotein 1

multiple interactions

[Benzo(a)pyrene co-treated with fluoranthene] affects the expression of SPP1 mRNA
[1-methylanthracene co-treated with fluoranthene] results in increased expression of SPP1 mRNA

PMID:17690111 PMID:28329830

NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162

G

sprouty-related, EVH1 domain containing 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of SPRED1 mRNA

NCBI chr 3:103,983,120...104,050,321
Ensembl chr 3:103,983,072...104,049,718

G

sprouty RTK signaling antagonist 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of SPRY2 mRNA

NCBI chr15:82,692,291...82,697,408
Ensembl chr15:82,692,143...82,698,009

G

sprouty RTK signaling antagonist 4

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of SPRY4 mRNA

NCBI chr18:30,436,513...30,451,426
Ensembl chr18:30,436,443...30,453,004

G

spectrin, beta, non-erythrocytic 2

multiple interactions

[Benzo(a)pyrene co-treated with fluoranthene] affects the expression of SPTBN2 mRNA

NCBI chr 1:202,002,970...202,045,343
Ensembl chr 1:202,002,970...202,044,283

G

SPT2 chromatin protein domain containing 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of SPTY2D1 mRNA

NCBI chr 1:97,531,495...97,549,616
Ensembl chr 1:97,531,508...97,549,581

G

squalene epoxidase

decreases expression
multiple interactions

fluoranthene results in decreased expression of SQLE mRNA
[1-methylanthracene co-treated with fluoranthene] results in decreased expression of SQLE mRNA

NCBI chr 7:90,867,973...90,883,623
Ensembl chr 7:90,868,011...90,883,618

G

SLIT-ROBO Rho GTPase activating protein 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of SRGAP3 mRNA

NCBI chr 4:145,839,369...146,070,556
Ensembl chr 4:145,840,078...146,070,575

G

sorcin

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of SRI mRNA

NCBI chr 4:25,973,493...25,997,879
Ensembl chr 4:25,966,750...25,998,077

G

signal transducing adaptor molecule

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of STAM mRNA

NCBI chr17:77,120,235...77,166,173
Ensembl chr17:77,120,158...77,166,467

G

STAM binding protein-like 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of STAMBPL1 mRNA

NCBI chr 1:231,699,620...231,745,034
Ensembl chr 1:231,699,995...231,745,032

G

StAR-related lipid transfer domain containing 10

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of STARD10 mRNA

NCBI chr 1:155,722,637...155,748,007
Ensembl chr 1:155,718,389...155,747,094

G

StAR-related lipid transfer domain containing 4

decreases expression
multiple interactions

fluoranthene results in decreased expression of STARD4 mRNA
[1-methylanthracene co-treated with fluoranthene] results in decreased expression of STARD4 mRNA

NCBI chr18:24,814,683...24,830,024
Ensembl chr18:24,817,107...24,830,024

G

stanniocalcin 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of STC1 mRNA

NCBI chr15:44,299,591...44,311,695
Ensembl chr15:44,299,621...44,310,264

G

serine/threonine kinase 40

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of STK40 mRNA

NCBI chr 5:138,380,049...138,417,802
Ensembl chr 5:138,381,159...138,417,796

G

syntaxin 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of STX3 mRNA

NCBI chr 1:208,617,018...208,686,240
Ensembl chr 1:208,639,115...208,685,805

G

SUN domain containing ossification factor

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of SUCO mRNA

NCBI chr13:74,192,808...74,257,896
Ensembl chr13:74,193,573...74,257,896

G

sulfite oxidase

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of SUOX mRNA

NCBI chr 7:1,103,149...1,107,156
Ensembl chr 7:1,103,151...1,107,038

G

synapse defective Rho GTPase homolog 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of SYDE1 mRNA

NCBI chr 7:11,032,931...11,038,917
Ensembl chr 7:11,032,898...11,039,869

G

synaptojanin 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of SYNJ2 mRNA

NCBI chr 1:46,518,594...46,621,919
Ensembl chr 1:46,518,709...46,633,687

G

TATA-box binding protein associated factor, RNA polymerase I subunit A

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of TAF1A mRNA

NCBI chr13:95,012,160...95,048,131
Ensembl chr13:95,029,225...95,048,087

G

TATA-box binding protein associated factor, RNA polymerase I subunit D

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of TAF1D mRNA

NCBI chr 8:12,146,511...12,156,647
Ensembl chr 8:12,146,605...12,156,618

G

TATA-box binding protein associated factor 4b

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of TAF4B mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of TAF4B mRNA]

NCBI chr18:5,952,737...6,086,408
Ensembl chr18:5,952,769...6,068,307

G

TATA-box binding protein associated factor 5

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of TAF5 mRNA

NCBI chr 1:245,958,428...245,973,914
Ensembl chr 1:245,958,428...245,973,914

G

tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of TANC2 mRNA

NCBI chr10:90,553,124...90,873,477
Ensembl chr10:90,553,002...90,868,756

G

TRAF family member-associated NFKB activator

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of TANK mRNA

NCBI chr 3:46,114,230...46,190,270
Ensembl chr 3:46,114,274...46,190,264

G

TatD DNase domain containing 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of TATDN2 mRNA

NCBI chr 4:146,845,156...146,865,708
Ensembl chr 4:146,845,156...146,860,897

G

TBC1 domain family, member 15

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of TBC1D15 mRNA

NCBI chr 7:50,804,553...50,860,272
Ensembl chr 7:50,804,012...50,860,175

G

TBC1 domain family, member 23

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of TBC1D23 mRNA

NCBI chr11:43,303,355...43,361,507
Ensembl chr11:43,303,355...43,361,503

G

TBC1 domain family, member 31

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of TBC1D31 mRNA

NCBI chr 7:89,427,354...89,506,894
Ensembl chr 7:89,426,780...89,506,894

G

TBCC domain containing 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of TBCCD1 mRNA

NCBI chr11:78,168,386...78,205,314
Ensembl chr11:78,168,388...78,205,523

G

t-complex 11 like 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of TCP11L2 mRNA

NCBI chr 7:19,150,241...19,185,135
Ensembl chr 7:19,150,252...19,185,095

G

TEF transcription factor, PAR bZIP family member

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of TEF mRNA

NCBI chr 7:113,317,191...113,341,783
Ensembl chr 7:113,317,283...113,341,783

G

testis expressed 261

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of TEX261 mRNA

NCBI chr 4:116,253,547...116,260,730
Ensembl chr 4:116,244,600...116,260,253

G

transforming growth factor, beta 1

multiple interactions
increases expression

TNF protein inhibits the reaction [fluoranthene results in increased expression of TGFB1 mRNA]

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

TGFB-induced factor homeobox 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of TGIF1 mRNA

NCBI chr 9:110,748,094...110,757,714
Ensembl chr 9:110,720,921...110,757,802

G

trans-golgi network protein 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of TGOLN1 mRNA

NCBI chr 4:104,663,356...104,671,208
Ensembl chr 4:104,663,353...104,671,164

G

thrombomodulin

multiple interactions
decreases expression

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of THBD mRNA
fluoranthene results in decreased expression of THBD mRNA

NCBI chr 3:135,863,366...135,867,018
Ensembl chr 3:135,862,835...135,867,193

G

thioesterase superfamily member 4

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of THEM4 mRNA

NCBI chr 2:181,953,550...181,974,708
Ensembl chr 2:181,953,550...181,974,708

G

thioesterase superfamily member 6

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of THEM6 mRNA

NCBI chr 7:106,606,570...106,609,747
Ensembl chr 7:106,606,570...106,609,746

G

TCDD-inducible poly(ADP-ribose) polymerase

increases expression
multiple interactions

fluoranthene results in increased expression of TIPARP mRNA
[1-methylanthracene co-treated with fluoranthene] results in increased expression of TIPARP mRNA
TNF protein inhibits the reaction [fluoranthene results in increased expression of TIPARP mRNA]

PMID:25268939 PMID:28329830

NCBI chr 2:149,753,682...149,780,327
Ensembl chr 2:149,753,682...149,780,327

G

TLC domain containing 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of TLCD1 mRNA

NCBI chr10:63,074,469...63,076,502
Ensembl chr10:63,074,469...63,076,501

G

TLC domain containing 3A

multiple interactions
decreases expression

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of TLCD3A mRNA
fluoranthene results in decreased expression of TLCD3A mRNA

NCBI chr10:61,057,470...61,065,293
Ensembl chr10:61,058,042...61,065,283

G

TLE family member 5, transcriptional modulator

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of TLE5 mRNA

NCBI chr 7:8,143,357...8,150,295
Ensembl chr 7:8,143,357...8,150,113

G

talin rod domain containing 1

decreases expression

fluoranthene results in decreased expression of TLNRD1 mRNA

NCBI chr 1:137,864,340...137,866,359
Ensembl chr 1:137,864,343...137,866,359

G

transmembrane protein 11

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of TMEM11 mRNA

NCBI chr10:45,542,753...45,557,570
Ensembl chr10:45,542,755...45,557,570

G

transmembrane protein 140

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of TMEM140 mRNA

NCBI chr 4:63,536,477...63,547,478
Ensembl chr 4:63,536,168...63,548,455

G

transmembrane protein 164

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of TMEM164 mRNA

NCBI chr X:106,288,019...106,448,642
Ensembl chr X:106,289,371...106,448,640

G

transmembrane protein 170A

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of TMEM170 mRNA

NCBI chr19:39,833,947...39,846,807
Ensembl chr19:39,833,980...39,846,783

G

transmembrane protein 175

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of TMEM175 mRNA

NCBI chr14:1,073,410...1,089,764
Ensembl chr14:1,073,523...1,089,819

G

transmembrane protein 19

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of TMEM19 mRNA

NCBI chr 7:50,958,884...50,985,601
Ensembl chr 7:50,958,888...50,986,809

G

transmembrane protein 254

multiple interactions
decreases expression

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of TMEM254 mRNA
fluoranthene results in decreased expression of TMEM254 mRNA

NCBI chr16:1,503,931...1,507,819
Ensembl chr16:1,503,933...1,507,895

G

transmembrane protein 39a

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of TMEM39A mRNA

NCBI chr11:62,160,631...62,189,964
Ensembl chr11:62,160,631...62,189,964

G

transmembrane protein 86A

decreases expression
multiple interactions

fluoranthene results in decreased expression of TMEM86A mRNA
[1-methylanthracene co-treated with fluoranthene] results in decreased expression of TMEM86A mRNA

NCBI chr 1:97,595,910...97,600,260
Ensembl chr 1:97,595,842...97,600,260

G

transmembrane protein 97

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of TMEM97 mRNA

NCBI chr10:63,438,228...63,447,311
Ensembl chr10:63,438,222...63,589,730

G

tumor necrosis factor

multiple interactions
increases response to substance

TNF protein inhibits the reaction [fluoranthene results in increased expression of IL4 mRNA]; TNF protein inhibits the reaction [fluoranthene results in increased expression of TGFB1 mRNA]; TNF protein promotes the reaction [fluoranthene results in increased expression of CXCL8 mRNA]; TNF protein promotes the reaction [fluoranthene results in increased expression of IL6 mRNA]; TNF protein promotes the reaction [fluoranthene results in increased secretion of CXCL8 protein]
TNF protein inhibits the reaction [fluoranthene results in increased expression of AHRR mRNA]; TNF protein inhibits the reaction [fluoranthene results in increased expression of CYP1A1 mRNA]; TNF protein inhibits the reaction [fluoranthene results in increased expression of TIPARP mRNA]; TNF protein promotes the reaction [fluoranthene results in increased expression of CYP1B1 mRNA]
fluoranthene results in increased susceptibility to TNF protein

PMID:18434080 PMID:25268939

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF alpha induced protein 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of TNFAIP3 mRNA

NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282

G

TNF alpha induced protein 6

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of TNFAIP6 mRNA

NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649

G

TNF receptor superfamily member 12A

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of TNFRSF12A mRNA

NCBI chr10:12,707,077...12,709,071
Ensembl chr10:12,689,890...12,709,045

G

TNF receptor superfamily member 1B

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of TNFRSF1B mRNA

NCBI chr 5:157,070,642...157,104,216
Ensembl chr 5:157,070,642...157,104,206

G

TNF receptor superfamily member 21

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of TNFRSF21 mRNA

NCBI chr 9:17,879,156...17,954,085
Ensembl chr 9:17,879,156...17,954,085

G

tumor necrosis factor receptor superfamily, member 22

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of TNFRSF22 mRNA

NCBI chr 1:198,840,452...198,860,713
Ensembl chr 1:198,840,453...198,856,309

G

tensin 4

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of TNS4 mRNA

NCBI chr10:84,021,965...84,041,346
Ensembl chr10:84,021,966...84,041,346

G

transducer of ErbB-2.1

decreases expression

fluoranthene results in decreased expression of TOB1 mRNA

NCBI chr10:79,163,093...79,165,131
Ensembl chr10:79,160,154...79,165,215

G

DNA topoisomerase I

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of TOP1 mRNA

NCBI chr 3:149,293,469...149,376,618
Ensembl chr 3:149,293,403...149,376,623

G

tumor protein p53

multiple interactions
increases expression

fluoranthene promotes the reaction [Benzo(a)pyrene results in increased expression of TP53 protein]
fluoranthene promotes the reaction [Benzo(a)pyrene results in increased expression of TRP53 mRNA]; fluoranthene promotes the reaction [Benzo(a)pyrene results in increased expression of TRP53 protein]; fluoranthene promotes the reaction [Benzo(a)pyrene results in increased phosphorylation of TRP53 protein]; TRP53 results in increased susceptibility to [Benzo(a)pyrene co-treated with fluoranthene]
fluoranthene results in increased expression of TRP53 protein

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

tumor protein p53 binding protein, 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of TRP53BP2 mRNA

NCBI chr13:94,088,769...94,145,436
Ensembl chr13:94,088,709...94,145,432

G

TNF receptor-associated factor 5

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of TRAF5 mRNA

NCBI chr13:103,569,944...103,618,747
Ensembl chr13:103,572,314...103,618,709

G

trafficking protein particle complex subunit 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of TRAPPC1 mRNA

NCBI chr10:54,045,598...54,047,184
Ensembl chr10:54,045,537...54,047,331

G

trafficking protein particle complex subunit 6A

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of TRAPPC6A mRNA

NCBI chr 1:79,158,587...79,165,502
Ensembl chr 1:79,158,529...79,165,493

G

tribbles pseudokinase 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of TRIB1 mRNA

NCBI chr 7:91,206,579...91,213,126
Ensembl chr 7:91,206,579...91,214,731

G

tribbles pseudokinase 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of TRIB3 mRNA

NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497

G

tripartite motif-containing 33

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of TRIM33 mRNA

NCBI chr 2:190,812,329...190,892,663
Ensembl chr 2:190,807,243...190,888,814

G

tRNA methyltransferase 10C, mitochondrial RNase P subunit

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of TRMT10C mRNA

NCBI chr11:44,584,388...44,589,466
Ensembl chr11:44,584,113...44,589,568

G

tRNA methyltransferase 13 homolog

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of TRMT13 mRNA

NCBI chr 2:204,533,630...204,547,711
Ensembl chr 2:204,533,632...204,546,843

G

tRNA methyltransferase 61A

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of TRMT61A mRNA

NCBI chr 6:130,737,230...130,743,251
Ensembl chr 6:130,737,219...130,743,243

G

TruB pseudouridine synthase family member 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of TRUB1 mRNA

NCBI chr 1:256,513,418...256,554,549
Ensembl chr 1:256,515,562...256,552,814

G

TSC22 domain family, member 3

multiple interactions

[1,2,5,6-dibenzanthracene co-treated with fluoranthene] affects the expression of TSC22D3 mRNA
[1-methylanthracene co-treated with fluoranthene] results in increased expression of TSC22D3 mRNA

PMID:18711122 PMID:28329830

NCBI chr X:104,217,898...104,277,886
Ensembl chr X:104,217,925...104,276,861

G

tetraspanin 15

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of TSPAN15 mRNA

NCBI chr20:30,130,528...30,174,912
Ensembl chr20:30,130,530...30,174,930

G

TSR1, ribosome maturation factor

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of TSR1 mRNA

NCBI chr10:59,760,420...59,771,868
Ensembl chr10:59,760,409...59,771,864

G

thiosulfate sulfurtransferase like domain containing 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of TSTD3 mRNA

NCBI chr 5:35,294,652...35,304,093
Ensembl chr 5:35,294,645...35,304,101

G

TTL family tubulin polyglutamylase complex subunit L1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of TTLL1 mRNA

NCBI chr 7:114,619,509...114,648,850
Ensembl chr 7:114,619,508...114,648,761

G

tweety family member 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of TTYH3 mRNA

NCBI chr12:13,996,831...14,025,457
Ensembl chr12:13,997,045...14,025,459

G

tubulin, alpha 1A

decreases expression
multiple interactions

fluoranthene results in decreased expression of TUBA1A mRNA
[1-methylanthracene co-treated with fluoranthene] results in decreased expression of TUBA1A mRNA

NCBI chr 7:130,113,214...130,116,880
Ensembl chr 7:130,081,032...130,196,186

G

tubulin, beta 5 class I

multiple interactions

[1,2,5,6-dibenzanthracene co-treated with fluoranthene] affects the expression of TUBB5 mRNA; [Benzo(a)pyrene co-treated with fluoranthene] affects the expression of TUBB5 mRNA

NCBI chr20:2,912,779...2,916,928
Ensembl chr20:2,912,778...2,916,940

G

trans-golgi network vesicle protein 23 homolog A

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of TVP23A mRNA

NCBI chr10:5,227,198...5,263,185
Ensembl chr10:5,227,220...5,263,180

G

twisted gastrulation BMP signaling modulator 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of TWSG1 mRNA

NCBI chr 9:105,533,116...105,567,460
Ensembl chr 9:105,533,136...105,567,479

G

thioredoxin interacting protein

multiple interactions
decreases expression

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of TXNIP mRNA
fluoranthene results in decreased expression of TXNIP mRNA

NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886

G

thioredoxin reductase 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of TXNRD1 mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of TXNRD1 mRNA]

NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863

G

transmembrane immune signaling adaptor Tyrobp

multiple interactions

[Benzo(a)pyrene co-treated with fluoranthene] affects the expression of TYROBP mRNA

NCBI chr 1:85,672,931...85,676,856
Ensembl chr 1:85,672,994...85,676,848

G

ubiquitin C

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of UBC mRNA

NCBI chr12:31,239,149...31,243,924
Ensembl chr12:31,239,152...31,243,925

G

ubinuclein 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of UBN1 mRNA

NCBI chr10:10,496,576...10,532,010
Ensembl chr10:10,496,576...10,532,010

G

UDP-glucose ceramide glucosyltransferase

multiple interactions

[1,2,5,6-dibenzanthracene co-treated with fluoranthene] affects the expression of UGCG mRNA
[1-methylanthracene co-treated with fluoranthene] results in increased expression of UGCG mRNA

PMID:18711122 PMID:28329830

NCBI chr 5:74,032,978...74,065,701
Ensembl chr 5:74,032,978...74,065,393

G

ubiquitin specific peptidase 36

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of USP36 mRNA

NCBI chr10:103,497,349...103,528,877
Ensembl chr10:103,497,349...103,528,877

G

ubiquitin specific peptidase 53

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of USP53 mRNA

NCBI chr 2:211,059,512...211,120,942
Ensembl chr 2:211,059,520...211,120,943

G

ubiquitin specific peptidase 54

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of USP54 mRNA

NCBI chr15:3,659,345...3,757,703
Ensembl chr15:3,659,240...3,757,711

G

vascular cell adhesion molecule 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of VCAM1 mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of VCAM1 mRNA]

NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958

G

vascular endothelial growth factor A

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of VEGFA mRNA; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of VEGFA mRNA]

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

vacuole membrane protein 1

increases expression

fluoranthene results in increased expression of VMP1 mRNA

NCBI chr10:71,405,058...71,505,045
Ensembl chr10:71,405,452...71,505,007

G

VPS37B subunit of ESCRT-I

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of VPS37B mRNA

NCBI chr12:32,560,047...32,589,015
Ensembl chr12:32,560,047...32,589,014

G

WW domain binding protein 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of WBP1 mRNA

NCBI chr 4:115,625,168...115,627,567
Ensembl chr 4:115,625,168...115,627,624

G

WD repeat domain 43

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of WDR43 mRNA

NCBI chr 6:23,845,499...23,884,846
Ensembl chr 6:23,845,499...23,884,846

G

WD repeat domain 83 opposite strand

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of WDR83OS mRNA

NCBI chr19:23,075,373...23,076,745
Ensembl chr19:23,075,376...23,076,894

G

Wnt family member 5A

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of WNT5A mRNA

NCBI chr16:3,697,032...3,718,230
Ensembl chr16:3,697,032...3,718,234

G

Wnt family member 9A

decreases expression
multiple interactions

fluoranthene results in decreased expression of WNT9A mRNA
[1-methylanthracene co-treated with fluoranthene] results in decreased expression of WNT9A mRNA

NCBI chr10:44,094,140...44,121,134
Ensembl chr10:44,094,140...44,121,133

G

xanthine dehydrogenase

increases expression
multiple interactions

fluoranthene results in increased expression of XDH mRNA
[1-methylanthracene co-treated with fluoranthene] results in increased expression of XDH mRNA

NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268

G

X-ray repair cross complementing 1

multiple interactions

[Benzo(a)pyrene co-treated with fluoranthene] affects the expression of XRCC1 mRNA

NCBI chr 1:80,140,495...80,168,705
Ensembl chr 1:80,141,207...80,168,701

G

yippee-like 2

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of YPEL2 mRNA

NCBI chr10:71,746,308...71,803,843
Ensembl chr10:71,746,311...71,803,911

G

zinc finger BED-type containing 5

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ZBED5 mRNA

NCBI chr12:26,807,652...26,813,706
Ensembl chr12:26,807,600...26,813,664

G

zinc finger and BTB domain containing 10

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ZBTB10 mRNA

NCBI chr 2:92,475,254...92,509,892
Ensembl chr 2:92,479,014...92,512,515

G

zinc finger and BTB domain containing 11

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ZBTB11 mRNA

NCBI chr11:44,598,694...44,652,559
Ensembl chr11:44,616,289...44,651,050

G

zinc finger and BTB domain containing 14

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of ZBTB14 mRNA

NCBI chr 9:109,333,440...109,338,646
Ensembl chr 9:109,331,028...109,338,632

G

zinc finger and BTB domain containing 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of ZBTB3 mRNA

NCBI chr 1:205,693,906...205,703,277
Ensembl chr 1:205,686,620...205,704,515

G

zinc finger CCCH type containing 12A

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ZC3H12A mRNA

NCBI chr 5:137,376,562...137,385,351
Ensembl chr 5:137,376,564...137,385,351

G

zinc finger CCCH type containing 3

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ZC3H3 mRNA

NCBI chr 7:107,440,694...107,525,451
Ensembl chr 7:107,440,694...107,525,451

G

zinc finger CCCH-type containing, antiviral 1 like

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of ZC3HAV1L mRNA

NCBI chr 4:66,994,192...67,003,207
Ensembl chr 4:66,994,199...67,001,620

G

zinc finger C4H2-type containing

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of ZC4H2 mRNA

NCBI chr X:60,525,706...60,546,519
Ensembl chr X:60,525,712...60,546,488

G

zinc finger CCHC-type containing 17

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of ZCCHC17 mRNA

NCBI chr 5:142,658,626...142,700,440
Ensembl chr 5:142,658,589...142,700,426

G

zinc finger CCHC-type containing 7

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ZCCHC7 mRNA

NCBI chr 5:58,992,558...59,173,308
Ensembl chr 5:58,993,290...59,173,300

G

zinc finger AN1-type containing 5

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ZFAND5 mRNA

NCBI chr 1:218,765,735...218,780,391
Ensembl chr 1:218,766,614...218,775,843

G

zinc finger protein 248

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of ZFP248 mRNA

NCBI chr 4:151,605,433...151,630,249
Ensembl chr 4:151,606,495...151,629,850

G

zinc finger protein 322a

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of ZFP322A mRNA

NCBI chr17:41,773,789...41,789,654
Ensembl chr17:41,773,782...41,790,078

G

zinc finger protein 330

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ZFP330 mRNA

NCBI chr19:25,313,655...25,324,958
Ensembl chr19:25,313,655...25,324,958

G

zinc finger protein 36

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ZFP36 mRNA

NCBI chr 1:83,669,084...83,671,564
Ensembl chr 1:83,669,084...83,671,564

G

zinc finger protein 36, C3H type-like 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ZFP36L1 mRNA

NCBI chr 6:98,930,705...98,935,748
Ensembl chr 6:98,930,718...98,935,748

G

zinc finger protein 418

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of ZFP418 mRNA

NCBI chr 1:66,581,406...66,594,247
Ensembl chr 1:66,581,287...66,594,242

G

zinc finger protein 608

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ZFP608 mRNA

NCBI chr18:48,304,873...48,412,846
Ensembl chr18:48,304,880...48,410,465

G

zinc finger protein 663

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in decreased expression of ZFP763 mRNA

NCBI chr 3:154,084,553...154,102,521
Ensembl chr 3:154,085,957...154,093,160

G

zinc finger protein 791

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ZFP791 mRNA

NCBI chr19:23,018,418...23,033,580
Ensembl chr19:23,018,918...23,033,504

G

zinc finger protein 9

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ZFP9 mRNA

NCBI chr 4:151,638,724...151,656,740
Ensembl chr 4:151,638,711...151,656,803

G

zinc finger protein 948

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ZFP948 mRNA

NCBI chr 1:61,366,068...61,396,300
Ensembl chr 1:61,368,076...61,395,282

G

zinc finger protein 955B

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ZFP955B mRNA

NCBI chr 7:12,610,224...12,625,537
Ensembl chr 7:12,610,196...12,622,587

G

zinc finger RANBP2-type containing 1

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ZRANB1 mRNA

NCBI chr 1:187,725,354...187,780,129
Ensembl chr 1:187,724,320...187,779,655

G

zinc finger, SWIM-type containing 4

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ZSWIM4 mRNA

NCBI chr19:23,927,845...23,952,970
Ensembl chr19:23,927,845...23,952,970

G

zinc finger, SWIM-type containing 6

multiple interactions

[1-methylanthracene co-treated with fluoranthene] results in increased expression of ZSWIM6 mRNA

NCBI chr 2:39,211,131...39,378,877
Ensembl chr 2:39,212,949...39,378,924

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	19841
role	19817
biological role	19815
aetiopathogenetic role	19196
carcinogenic agent	18519
polycyclic arene	17033
ortho- and peri-fused polycyclic arene	16282
fluoranthene	757
7,10-bis(4-bromophenyl)-8,9-bis(4-octylphenyl)fluoranthene	0
7,10-bis(4-bromophenyl)-8,9-diphenylfluoranthene	0
7,10-bis(4-bromophenyl)-8-nonyl-9-octylfluoranthene	0
Path 2
Term	Annotations
CHEBI ontology	19841
subatomic particle	19839
composite particle	19839
hadron	19839
baryon	19839
nucleon	19839
atomic nucleus	19839
atom	19839
main group element atom	19789
main group molecular entity	19789
s-block molecular entity	19626
hydrogen molecular entity	19613
hydrides	19120
organic hydride	18689
organic fundamental parent	18689
hydrocarbon	18435
cyclic hydrocarbon	17225
arene	17205
polycyclic arene	17033
ortho- and peri-fused polycyclic arene	16282
fluoranthene	757
7,10-bis(4-bromophenyl)-8,9-bis(4-octylphenyl)fluoranthene	0
7,10-bis(4-bromophenyl)-8,9-diphenylfluoranthene	0
7,10-bis(4-bromophenyl)-8-nonyl-9-octylfluoranthene	0

paths to the root